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Abstract 
Against a backdrop of global antibiotic resistance and increasing awareness of the importance of the 
human microbiota, there has been resurgent interest in the potential use of bacteriophages for 
therapeutic purposes, known as phage therapy. A number of phage therapy phase I and II clinical 
trials have concluded, and shown phages don’t present significant adverse safety concerns. These 
clinical trials used simple phage suspensions without any formulation and phage stability was of 
secondary concern. Phages have a limited stability in solution, and undergo a significant drop in 
phage titre during processing and storage which is unacceptable if phages are to become regulated 
pharmaceuticals, where stable dosage and well defined pharmacokinetics and pharmacodynamics 
are de rigueur. Animal studies have shown that the efficacy of phage therapy outcomes depend on 
the phage concentration (i.e. the dose) delivered at the site of infection, and their ability to target and 
kill bacteria, arresting bacterial growth and clearing the infection. In addition, in vitro and animal 
studies have shown the importance of using phage cocktails rather than single phage preparations to 
achieve better therapy outcomes. The in vivo reduction of phage concentration due to interactions 
with host antibodies or other clearance mechanisms may necessitate repeated dosing of phages, or 
sustained release approaches. Modelling of phage-bacterium population dynamics reinforces these 
points. Surprisingly little attention has been devoted to the effect of formulation on phage therapy 
outcomes, given the need for phage cocktails, where each phage within a cocktail may require 
significantly different formulation to retain a high enough infective dose. 
 
This review firstly looks at the clinical needs and challenges (informed through a review of key animal 
studies evaluating phage therapy) associated with treatment of acute and chronic infections and the 
drivers for phage encapsulation. An important driver for formulation and encapsulation is shelf life and 
storage of phage to ensure reproducible dosages. Other drivers include formulation of phage for 
encapsulation in micro- and nanoparticles for effective delivery, encapsulation in stimuli responsive 
systems for triggered controlled or sustained release at the targeted site of infection. Encapsulation of 
phage (e.g. in liposomes) may also be used to increase the circulation time of phage for treating 
systemic infections, for prophylactic treatment or to treat intracellular infections. We then proceed to 
document approaches used in the published literature on the formulation and stabilisation of phage for 
storage and encapsulation of bacteriophage in micro- and nanostructured materials using freeze 
drying (lyophilization), spray drying, in emulsions e.g. ointments, polymeric microparticles, 
nanoparticles and liposomes. As phage therapy moves forward towards Phase III clinical trials, the 
review concludes by looking at promising new approaches for micro- and nanoencapsulation of 
phages and how these may address gaps in the field. 
 
Keywords: antibiotic resistance; bacteriophage; encapsulation; phage therapy; pharmacodynamics  
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Introduction 
The discovery of antibiotics and the subsequent control of bacterial infections may be regarded as a 
significant achievement of modern medicine. Surgery, transplantation and chemotherapy rely heavily 
on the control of bacterial infections. Broad spectrum antibiotics are highly attractive since they may 
be used against a wide range of bacteria without the need to identify the infection causing bacterial 
agent. This advantage has also resulted in significant misuse and overuse of antibiotics contributing to 
the emergence of antibiotic resistance [1]. Bacterial resistance to antibiotics has become a significant 
problem in the treatment of a wide range of infections where the bacteria commonly causing the 
infections have become highly resistant to many classes of antibiotics including third generation 
cephalosporins, carbapenems and fluoroquinolones [2]. Recent evidence of plasmid mediated colistin 
resistance in Enterobacteriacea is particularly troubling [3]. Between 1940 and 1962 more than 20 
new classes of antibiotics came to market; since then the antibiotic pipeline has produced only two 
new classes [4]. Coates et al. [4] estimate that to stem the rising tide of antibiotic resistance 20 new 
classes of antibiotics are urgently needed. It is highly unlikely that this goal will be achievable even if 
governments provided stronger economic incentives to industry to develop new broad spectrum 
antibiotics. Czaplewski et al. [5] call for a sustained, concerted and coordinated international effort and 
discuss the need to invest in the development of alternatives to antibiotics (non-compound 
approaches) including probiotics, vaccines as well bacteriophage and phage derived lysins. 
 
Bacteriophage as novel antimicrobials 
Bacteriophage (viruses that infect bacteria) are highly abundant in the environment and may be the 
source of low cost antimicrobials. The focus of recent phage therapy approaches is on the use of lytic 
tailed phage all of which belong to the Caudovirales and include the Myoviridae, Siphoviridae and 
Podoviridae families [6]. Members of the Caudovirales have an icosahedral capsid head that contains 
double-stranded DNA (15 - 500 Kbp), and a tail with surface receptor proteins that interact with 
surface features on the host bacterium [7]. Successful phage therapy requires interaction between the 
phage and the bacterium resulting in adsorption of the phage to the host bacterium followed by 
injection of the phage DNA. The pharmacodynamics of this process has been modelled using 
mathematical models based on colloidal interactions [8–10]. Upon infection, the phage replication 
cycle ensues culminating (after a short latency period) in cell lysis and the liberation of multiple phage 
virions (with a burst size that is typically between 10 and 100, [11]). Gill and Hyman [12] and Weber-
Dabrowska et al. [13] provide an overview of key considerations related to phage choice, isolation and 
purification for phage therapy. Phage therapy practice relies on the isolation of naturally occurring 
phage abundantly found in the environment [14]. Typically, phage are isolated from the environment 
and screened against commonly occurring pathogenic bacterial strains (to identify host ranges) and 
then evaluated using in vitro and in vivo animal models. The limitation of host ranges is overcome 
through the use of phage cocktails to ensure sufficient coverage of commonly occurring strains and 
the use of phage mixtures targeting different receptors reduces the probability of encountering phage 
resistant bacterial mutants. Phages are generally manufactured using standard fermentation process 
technology. In brief, host bacteria are grown in liquid culture in a bioreactor. During the log growth 
phase, phages are added to the bioreactor to infect the bacteria. Incubation of phage with bacteria 
results in phage adsorption to the bacteria, infection and following a short lag period, release of 
bacteriophage virions. The resulting lysate contains the product (the amplified phage) along with 
bacterial debris and residual fermentation media. Removal of cellular debris is typically done using 
centrifugation and/or filtration. Ion exchange, gel filtration etc. can be used to further purify the 
bacteriophage (e.g. for the removal of endotoxin for Gram negative bacteria). Typically phage may 
then be re-suspended in simple saline or buffer and stored under refrigerated conditions or processed 
further e.g. spray dried to improve storage shelf life or encapsulated in micro- or nanoparticle 
formulations. 
 
Phage are unique antimicrobials in that in the presence of host bacteria, they are able to increase 
their numbers by infecting the bacteria and producing virion progeny whilst minimally affecting the 
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overall microbiota and body tissues. Phage carrying polysaccharide depolymerases (polysaccharide 
degrading enzymes) in their structure may be able to disrupt biofilms [15–17]. For example 
Enterococcus and Staphylococcus phage capable of destroying biofilms have been reported [18,19]. 
In addition to their potential as human biotherapeutics, phage are being developed for agricultural use 
to rid the environment and domestic animals of pathogens that could contaminate the food supply 
chain [20], in aquaculture for the treatment of fish pathogens [21] and for the control of infections in 
intensively farmed poultry [22,23]. Recent advances in molecular biology and sequencing technology 
have improved our basic understanding of how bacteriophage interact with bacteria and have opened 
new possibilities for utilising phage, including genetically engineered phage, for potential therapeutic 
and diagnostic applications [7,24]. 
 
Phage therapy for Acute and Chronic Infections 
Most of the recent phage therapy studies (using small vertebrate animals) have investigated 
treatments focusing on acute infections (Table 1). In acute infections the specific infection causing 
bacterium may be identified using suitable rapid diagnostic methods (e.g. lateral flow assays, PCR, 
MALDI-TOF Mass Spectrometry). In such instances, narrow spectrum antimicrobials such as 
bacteriophages may provide a suitable therapeutic alternative where organisms are resistant to 
frontline antibiotics or to reduce the use of broad spectrum antibiotics as part of a global effort towards 
antibiotic stewardship. An example of this is in cases of urinary tract infections where a significant 
proportion of the cases are caused by a particular pathotype Escherichia coli with specific virulence 
factors [25]. Animal studies have shown that phage may be effective in certain instances e.g. in 
treating acute respiratory infections caused by Pseudomonas aeruginosa [26–28] and in the treatment 
of systemic infections caused by S. aureus [29]. A significant focus of phage therapy studies in 
animals has been around respiratory infections, gastrointestinal infections and infections of the skin 
and wounds (Table 1). Phage therapy studies with animals has shown that in certain instances, it may 
help in reducing the densities of the infecting bacterial populations to levels that may allow the host 
immune response to mount a successful defence and clear the infection [26,27,30]. 
 
A number of in vivo phage studies (with animals and humans) have suggested that phage therapy 
may be beneficial in the treatment of difficult to treat antibiotic resistant pulmonary infections (e.g. 
cystic fibrosis [26] and pneumonia [31,32]), topical and wound infections [33,34] and gastrointestinal 
infections [35].  
 
Challenges of antibiotic resistance for respiratory infections 
Cystic fibrosis (CF) is a genetic disease of the lung resulting in reduced hydration and thickening of 
secretions covering the respiratory epithelium. Highly viscous mucus is not cleared by the epithelial 
cells and eventually leads to chronic inflammation and bacterial infections. Two common bacterial 
strains isolated from sputum are Staphylococcus aureus and Haemophilus influenzae, which are also 
one of the first to infect the lungs during childhood [36]. S. aureus can generally be controlled with 
antibiotics but infection usually predisposes chronic colonization. The main pathogen infecting the 
pulmonary epithelium is Pseudomonas aeruginosa, which grows in biofilms within the CF lungs [37]. 
Several pulmonary pathogens are capable of forming biofilms in which the bacteria are encased in 
exopolysaccharide (EPS) and are less metabolically active [38]. The extracellular matrix in the biofilm 
impairs the action of antibiotics acting as a diffusional barrier. The low metabolic activity of the 
bacteria in the biofilm also limits the efficacy of many classes of antibiotics that target various 
metabolic pathways. Some bacteriophage may be able to degrade biofilms and infect bacteria 
residing within them [39,40]. Burkholderia cenocepacia are opportunistic pathogens in CF causing 
acute pulmonary disease and sepsis or chronic infection characterised by accelerated decline in lung 
function. Multidrug resistant phenotypes are exhibited by most strains. There is a need for alternative 
therapies to treat B. cenocepacia; several virulent phage for B. cenocepacia have been characterised. 
A number of in vivo phage therapy studies have looked at P. aeruginosa [26,27,41] and B. 
cenocepacia [42] infections in animal models.  
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Ventilator-associated-pneumonia (VAP) occurs often in patients in an intensive care unit setting. A 
clear respiratory airway is a necessity for patient survival; after being intubated and receiving 
mechanical ventilation, patients suffer from pneumonia caused by infection with P. aeruginosa, S. 
aureus, Streptococcus pneumoniae, H. influenzae and Acinetobacter baumanii which take advantage 
of the weakened immune system of the patient. One of the major problems is antibiotic resistance. 
Klebsiella sp., Enterobacter sp., Serrati sp., and Burkholderia sp., have also been reported as 
infecting bacteria. Klebsiella pneumoniae is an opportunistic bacterial pathogen responsible for much 
community-acquired pneumonia and a significant proportion of hospital-acquired pneumonia [31]. It is 
a leading cause of pneumonia morbidity and mortality with resistance to carbapenems and other 
antibiotics [43]. A number of in vivo phage therapy studies have looked at B. cepacia [42] and K. 
pneumonia [31,32] infections in animal models. 
 
Tuberculosis (TB) is a global health problem; one-third of the world’s population is infected with 
Mycobacterium tuberculosis (Mtb), the agent of TB, and at risk of developing disease and transmitting 
infection. Annually there are over 10 million new cases of TB and an estimated 1.4 million deaths [44]. 
Multidrug resistant tuberculosis cases are a significant healthcare problem with extensively drug 
resistant M. tuberculosis practically untreatable in low-income countries [45]. Multi-drug resistant 
(MDR) Mtb strains are resistant to isoniazid and rifampicin, two of the frontline antibiotics used to treat 
TB. The World Health Organisation (WHO) estimate there were nearly 500,000 new cases of MDR TB 
in 2015 [44]. Most alarming are the development of extensively drug resistant (XDR) strains, which 
are additionally resistant to second line antibiotics. Although antibiotic treatment rapidly reduces the 
infectiousness of patients, those with drug-resistant infections remain infectious during therapy until 
the drug resistance is identified and the treatment regimen is changed. Treatment for TB is protracted, 
requiring antibiotics to be taken for at least 6 months, rising to two years for MDR infections. The 
antibiotics can have undesirable side effects, and interruptions to therapy (intermittent supply or 
patient non-compliance) provide the opportunity for the development of drug resistance and treatment 
failure. There is therefore, an urgent need for new therapies to treat TB and also to shorten length of 
treatment. The Mtb bacillus is transmitted in aerosol droplets and therapies which reduce patient 
infectiousness or prevent the establishment of new infections will also have great impact on TB 
control. Infection is established in a new host when inhaled Mtb bacilli in the lower respiratory tract are 
engulfed by alveolar macrophage [46]. The bacilli resist usual macrophage killing mechanisms and 
replicate, until such time that the immune response triggers recruitment of systemic mononuclear cells 
which surround the focus of infection and form a granuloma. The centre of the granuloma becomes 
hypoxic, pH drops and conditions no longer support bacterial growth. Instead the Mtb bacilli remain in 
a dormant state with low metabolic activity, until such time that the immune system weakens, the 
granuloma breaks down and with this the bacilli reactivate and replicate once more. During this active 
TB disease the patient excretes large number of bacilli when they cough and can transmit the 
infection to new susceptible hosts. A number of recent papers have started looking at phage therapy 
for the treatment of TB infections [47,48]. 
 
Challenges of antibiotic resistance for wounds 
Chronic wounds are a severe worldwide problem. A recent prevalence study estimated 2.2 million 
wounds managed by the UK National Health Service (NHS) in 2012/2013 costing the UK NHS £5.3 
billion [49]. Studies suggest that wound management accounts for over half of community health 
nurse resources in European settings [50]. The majority of chronic wounds are colonised with bacteria 
that form biofilms, thereby compromising wound healing by making them more refractory to treatment 
and slow tissue repair by stimulating chronic inflammation at the wound site [51]. Antimicrobials 
including antibiotics and antiseptics are used clinically to decrease the bacterial load and promote 
wound healing [52]. However, systemic antibiotic therapy may be of little benefit due to poor diffusion 
of antimicrobials through the biofilm and the poor efficacy of antibiotics against bacteria with reduced 
metabolic activity. This reduced activity increases antibiotic tolerance since many classes of 
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antibiotics are only effective against actively dividing bacteria by targeting peptidoglycan produced in 
the cell wall (β-lactams), protein (aminoglycoside) synthesis, or DNA replication (quinolones) [53]. 
Polymicrobial biofilms in chronic wounds are recognised as an important factor in the failure to 
achieve wound healing in a timely fashion. As an example, diabetic foot infections (DFI) typically tend 
to be polymicrobial with aerobic gram-positive cocci, especially staphylococci, the most common 
causative microorganism [54]. S. aureus and P. aeruginosa are considered important pathogens in 
antibiotic resistant wound infections. A number of animal studies have looked at phage therapy for 
treating S. aureus and P. aeruginosa wound infections [33,34]. 
 
Challenges of antibiotic resistance for gastrointestinal infections 
Enteric pathogens form a large part of the healthcare burden around the globe. The most common 
infection causing bacteria are Clostridium difficile causing C. difficile associated diarrhoea [55], 
Shigella dysenteriae causing shigellosis [56], Escherichia coli causing gastroenteritis [57], Vibrio 
cholerae causing cholera [58], Salmonella enterica causing salmonellosis [59], Listeria 
monocytogenes causing listeriosis [60] and Helicobacter pylori causing chronic gastritis [61]. The 
primary route of infection in low income countries is through the faecal-oral route or from 
contaminated food and water [62]. Treatment usually involves antibiotics however, with emerging 
antibiotic resistance, infections with antibiotic resistant organisms is on the rise, hence the need for 
alternative therapy options. In addition to humans, these enteric pathogens are also capable of 
infecting farm animals resulting in high antibiotic use for animal husbandry, emerging resistance and 
risk of contamination of the food chain. Numerous studies have evaluated the potential of phage 
therapy for the treatment of gastrointestinal infections caused by E. coli, S. enterica, V. cholera and C. 
difficile (Table 1).  
 
Phage-Bacterium Population Dynamics - The Need for Bacteriophage Encapsulation 
There are a number of specific features regarding phage-bacterium dynamics that are worth 
highlighting in the context of phage therapy. Bacterial killing by phage is dependent on phage particles 
adsorbing to the target bacteria [9]. Phage-bacterium binding kinetics may be modelled as a simple 
first order process with respect to the concentrations of bacteria and phage populations respectively 
[8,63]. Payne and Jansen [63] developed a mathematical model focusing on the dynamics of phage 
infection of bacteria during the bacterial exponential growth phase. Levin and Bull [8] extended the 
model to include the effect of bacterial mutation leading to phage resistant populations and the effect 
of the immune response in combating bacterial infections. Cairns et al. [9] fitted in vitro phage-bacteria 
population dynamics (time series data for Camplylobacter jejuni) to extract interaction parameters; the 
model included the rate at which resistant cells arise by mutation from a susceptible population. Their 
model and that of Levin and Bull [8] helps explain the in vitro observations (see Tanji et al. [64]) 
showing increase in concentration of resistant bacteria in the presence of high concentrations of 
phage. In in vitro studies, the rate of growth of resistant bacteria tends to be similar to that of the 
original susceptible population. The fitted rate of mutation was found to be of the order of 10
-5
 h
-1
 
(which is relatively fast). An alternative explanation may be the presence of a small number of 
resistant cells present at the start of the culture [9]. Measures to suppress growth of resistant bacteria 
would include use of multiple phage strains incorporating phage that bind to different receptors. The 
purpose of the modelling is to illustrate a number of important features that provide insights that may 
help inform in vivo phage therapy. Modelling can be used to determine the effects of parameters such 
as the dose of phage delivered, the rate at which it is delivered (e.g. controlled release) or bacteria 
growth rate, on phage-bacteria population dynamics and on phage therapy outcomes. It may be used 
to help interpret results of in vivo studies and inform the design of future studies. 
 
We have undertaken numerical simulations of phage-bacterium population dynamics for an acute 
infection model to highlight key features including the dynamics of phage interaction with bacteria 
during the exponential growth phase (model equations and parameters used for simulations are laid 
out in the accompanying Appendix). Our model is similar to that of Levin and Bull [8] for phage-
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bacteria interactions incorporating phage resistant bacteria arising from bacteria mutation (we have 
used the mutation rate used by Cairns et al. [9]; we haven’t included a model of the immune 
response). Phage growth is determined by a number of parameters, the phage-bacteria adsorption 
rate constant, burst size (the number of phage released for each infected bacteria), latent period 
(following infection how long it takes for the phage replication cycle to be completed in a bacterial 
cell), the bacteria growth rate, phage and bacteria elimination rates due to host response and the 
initial concentrations of bacteria and phage [65]. A unique feature of our model is that we have also 
incorporated the effect of controlled release of phage which to our knowledge has not previously been 
done. 
 
Our simulations demonstrate the conditions under which phage therapy may be able to limit the 
proliferation of bacterial populations. High phage densities are needed in order to arrest the growth of 
phage susceptible bacteria (Figure 1 a, b). We have indicated an arbitrary upper bacterial 
concentration threshold of 10
9
 CFU/ml as an aid to guide the reader’s eye. Adsorption of phage to 
bacteria results in an initial drop in phage concentration (see experimental results by Cairns et. al. [9] 
with Campylobacter jejuni showing this). The timing of rapid in situ phage amplification is highly 
dependent on the concentration of the bacteria [9]. Successful amplification of phage is dependent on 
high bacterial concentration hence efficient killing is not achieved until both phage and bacteria 
concentration increase significantly (Figure 1 b). See also experimental results in support of this in the 
work by Tanji et al. [64]. Resistant bacteria quickly become the dominant population (Figure 1 a, b) 
unless a phage mixture (cocktail) is used containing high doses of the different phage strains capable 
of killing the resistant mutant population (Figure 1 c, d). It is known that phage clearance mechanisms 
rapidly reduce the phage concentration in the absence of host bacteria [58]. 
 
Using high initial bacterial concentration, a high phage dose is quickly able to arrest the rise of 
bacterial growth (Figure 2 a). Tanji et al. [64] show this for E. coli using an in vitro chemostat 
experimental  system. However, if low starting concentrations of bacteria are present, phage 
concentrations decay significantly and phage are unable to amplify and achieve a sufficiently high 
concentration to eradicate the infecting bacteria until the bacteria have had time to grow bacterial 
numbers substantially (Figure 2 b). In such circumstances it takes time for the bacterial population to 
grow before phage are able to adequately multiply in situ and then arrest bacterial growth 
(experimental results by Cairns et al. [9] show this). During this delay in bacterial concentration 
growth, phage concentrations may decay significantly thereby resulting in poor phage therapy 
outcomes. If phage are administered prophylactically too early prior to infection or at the early onset of 
infection (when the bacteria concentration is low), clearance of phage by the host immune system or 
by other mechanisms (e.g. shortening of intestinal transit times during diarrhoea) may result in 
lowering of the in situ phage concentration resulting in poor phage therapy outcomes (Figure 2 b). 
Under such conditions encapsulation may be a good strategy (Figure 2 c). Encapsulation of phage 
and their slow controlled release may help in ensuring that the in situ phage concentration remains at 
a therapeutically effective level (over a realistic time period) allowing phage to amplify once the 
bacteria concentration increases to levels sufficient for in situ phage amplification (Figure 2 c). 
 
Our simulations show that the in vivo phage concentration at the site of infection is an important 
parameter governing the efficacy of phage therapy. Loss of phage activity during formulation and 
storage, or phage inactivation due to the in vivo environment (e.g. acidic pH of the stomach or 
enzymatic activity) may result in poor phage therapy outcomes. These issues have received little 
attention in phage therapy literature. Research is therefore needed in the area of phage formulation to 
ensure phage titre remains stable during storage (e.g. over a 24 month period). Phage cocktails 
necessitate careful consideration of formulation conditions as each type of phage making-up the 
cocktail may require individually tailored formulations to ensure phage viability and stability during 
storage. 
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Phage therapy animal studies – acute infections 
 
Key points arising from reviewing phage therapy literature focusing on acute infections in animals 
 
Most in vivo phage therapy studies (in animals) have delivered the phage and bacteria dosed 
simultaneously together (Table 1). Typically, a high ratio of phage to bacteria has been used (phage 
concentrations 10 – 1000 times higher than the infective dose of bacteria). Phage treatment of acute 
infections caused by both Gram positive and Gram negative bacteria have been studied (Table 1). 
 
Phage have been administered using different delivery routes including intramuscular [34,66–69], 
subcutaneous [29,31–34,42], intraperitoneal [31,34,67,70–72], intravenous [29,68], intranasal [26–
28,42], orogastrically [57,58,64,70,73–81], intracranial [69] or added to animal feed [75,82] or water 
[83]. The route of phage administration has been shown to affect efficacy outcomes [34,42,66]. In a 
number of studies intraperitoneal delivery was shown to result in higher concentrations of systemic 
phage, delivered earlier, remaining in circulation for longer and allowing phage access to numerous 
host organs including lungs, spleen and kidneys ([34], [32]). Better therapy outcomes were seen for 
lung infections when phage were dosed using the intraperitoneal or systemic route instead of using 
pulmonary delivery [31]. 
 
A number of in vivo animal studies have shown dose dependent recoveries with high doses of phage 
resulting in better clinical outcomes [33,66–68]. Delaying the start of phage treatment post infection 
typically resulted in poor outcomes [33,67,68]. This was attributed to high growth rates resulting in 
high concentrations of replicating bacteria overwhelming the immune system with bacterial toxins [68].  
 
Inoculation of control animals (not infected with bacteria) with high phage doses was shown not to 
result in adverse health symptoms in animals [67]. A number of in vivo studies reported rapid drop in 
phage titre in the absence of host bacteria suggesting clearance by the host immune response or 
other removal mechanisms [32,58]. Encapsulation of phage in liposomes (for treating gastrointestinal 
infections) was shown to increase the retention time of phage in the host with better therapeutic 
efficacy [31]. 
 
In situ amplification of phage (at high phage doses) has been observed in some instances [71]. 
Frequent administration of high phage doses was found to result in better outcomes [64,76,78,80]. 
This is an important point considering in vivo phage-bacteria dynamics. Better phage therapy 
outcomes were noted when both phage and bacteria concentrations tend to be high. Phage titre 
reduction in vivo may result in poor phage therapy results when bacterial concentrations may be too 
low for rapid phage amplification. Reduction in phage titre may also explain results of a number of 
studies that evaluated prophylactic phage therapy with mixed results [70,73,75,79,80,83]. Use of 
phage cocktails rather than single phage was found to yield better results [58,64] and in some 
instances reduced the chances of finding phage resistant mutants. A number of studies did find phage 
resistant mutants [66,69]. The complex architecture of the intestinal tract was found to present a 
challenge for phage therapy. Temporary reduction in bacterial faecal shedding attributed to phage 
treatment was typically followed by an increase in faecal bacterial concentration without clearance of 
gastrointestinal infections [57,58,75,77,83].  
 
Results of a number of animal studies suggest that stopping rapid amplification in bacterial numbers is 
an important factor in therapy outcomes [26–28]. Arresting infection by early administration of high 
phage dose when the bacteria are also highly susceptible to phage infection was found to correlate 
with better phage therapy outcomes. Administration of high concentrations of phage may result in 
multiple phage particles adsorbing per bacterial cell which may lead to bacterial cell lysis due to 
phage binding without phage virion production. Delbruck [84] coined the term lysis from without. Large 
numbers of phage adsorbing to the bacterial cell wall may lead to cell wall damage due to the 
enzymatic action of tailed phage enzymes acting on the cell membrane [85]. 
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Infection is generally induced in animal models with a single bacterial species, however, even single 
bacterial triggered infections necessitate the use of phage cocktails rather than single phage 
treatments. This is because phage mixtures targeting different receptors reduce the probability of 
encountering phage resistant bacterial mutants (see modelling section above). Denou et al. [86] 
suggest that cocktails containing between 10 and 16 phage may be needed to cover half to two thirds 
of E. coli strains (representing the five main pathogenic types isolated from patients suffering from 
diarrhoea) in order to cure E. coli related diarrhoea. Cocktails of phage may also provide synergistic 
effects such as access to bacteria in mucus and biofilms with a phage possessing biofilm/mucus 
degrading enzymes enhancing access within mucus/biofilms for other phage better suited to killing the 
bacteria [87]. This point has significant implications for phage formulation since different phage within 
a cocktail may need different formulation ingredients to aid shelf life during storage in order to retain 
infectivity. A number of animal studies (discussed below) have shown that regular repeated doses of 
high phage titres resulted in better outcomes rather than a single dose. Encapsulation of phage in 
controlled release systems may allow constant release (zero order release) of phage e.g. using 
readily available technologies such as osmotic pumps or constant reservoir systems used in the 
pharmaceutical industry. Vandenheuvel et al. [88] discuss the importance of phage stability and the 
unacceptability of phage titre drop in view of pharmaceutical regulations. The results of animal studies 
(above) provide strong evidence of the need to deliver high titres of phage at the site of infection. 
Phage dose-response studies in animals suggest that a drop in titre of 1-log during storage could 
result in phage therapy failure. Reduction in phage titres due to phage inactivation attributed to 
stomach acidity was partly blamed for failure of a recent clinical trial aiming to show reduction in acute 
bacterial diarrhoea symptoms in children using phage therapy [35]. 
 
The pharmacokinetics of phage delivery to various animal organs depended on the route of 
administration. In a number of studies, intraperitoneal delivery of phage resulted in higher 
concentrations of phage in systemic circulation and those found in different organs including lungs. 
Encapsulation of phage in liposomes was found to increase the length of systemic circulation of 
phage. There is some evidence in literature that phage encapsulated in liposomes may treat 
intracellular infections (discussed later). 
 
Bacteriophage have a narrow host range. They are specific not only in terms of killing a particular 
species, but often they only target a sub set of strains within the species. In an outbreak situation 
where the causative agent and strain information is available, selection of a relevant phage for 
therapy may not be a problem [26]. However, as phage host range is narrow, rapid diagnosis of the 
causative agent and the strain would benefit accurate phage selection. Most phage therapy studies in 
model animal systems (discussed above) have used simple phage solutions prepared immediately 
prior to use. Phage banks may need to regularly screen phage against common infection causing 
strains and manufacture these in batches to make them readily available. The phage would need to 
be processed in such a manner so as to ensure long shelf life (typically 12 months) e.g. formulated in 
excipients and spray dried or freeze dried to ensure accurate dosage at the time of therapy. 
 
Characterisation of the kinetics of phage binding to target bacterium and in vitro evaluation of phage -
bacterium population dynamics as part of the selection tests (e.g. host range, presence of integrase 
genes) ascertaining the suitability of phage for therapeutic use is often overlooked and needs greater 
attention. 
 
A detailed list of literature studies covering phage therapy in various animal models is provided in 
Table 1 and more detailed commentaries on some selected papers are now given as follows. 
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Parenteral phage delivery (animal studies) 
A number of animal studies have looked at parenteral delivery of lytic bacteriophage following delivery 
of an infectious dose of bacteria (Table 1). Early work by Smith et al. [66] demonstrated the potential 
of intramuscular and intravenous administration of phage (10
8
 PFU/mouse) against E. coli infection 
(intramuscular injection of LD50 dose of 10
7
 CFU/mouse) in a mouse model. The effect of delaying 
treatment (8 h delay in treatment) showed favourable results. Prophylactic treatment up to 2 days 
before induced infection resulted in significant protection in animals. Intramuscular injection of 
bacteria resulted in high concentration of bacteria at the site of infection and in the blood, spleen and 
liver ~ 24 h post-inoculation. Within 5 min of phage administration, high phage numbers were found in 
the muscle, blood, spleen and liver. They persisted for shorter durations in the blood and liver 
compared with the inoculated muscle and spleen. Phage resistant mutants were found at the site of 
infection but were considered much less virulent.  
 
Barrow et al. [69] inoculated (intramuscularly (septicemia model) and intracranially (meningitis model)) 
newly hatched and 3 week old chickens with E. coli and phage and showed dose dependent recovery. 
Administration of higher concentration of phage resulted in significantly better outcomes. The same 
study also evaluated oral E. coli administration to Aberdeen Angus Calves with concomitant 
intramuscular phage delivery. The phage were unable to arrest the intestinal growth of E. coli and the 
presence of phage resistant mutant strains were found in the gut one day following E. coli inoculation 
and two days later in the blood (indicating translocation of phage from the gut into blood e.g. through 
intra-abdominal abscesses) of the infected calves. This study showed the importance of phage dose 
and route of delivery on therapy outcomes (mortality).  
 
Using a E. faeceium bacteremia mouse model Biswas et al. [67] investigated the effect of phage dose 
in E. faecium infected mice (concomitant delivery of phage and bacteria delivered via intraperitoneal 
injection) as well as the effect of delaying the start of phage treatment (5h, 8h, 12h, 16h and 24h after 
inoculation with bacteria). The severity of illness symptoms exhibited by mice was correlated with the 
bacterial concentration in the blood and this was shown to be dependent on the concentration of 
phage used for treatment. Mice inoculated with high titres of phage suspension (without infection with 
bacteria) showed no adverse symptoms. 24 h delay in phage treatment resulted in 60% (3 out of 5) of 
the mice dying after 96 h. The dosage and the timing of the delivery of phage was found to be 
important in arresting bacterial growth and in mice recovery.  
 
Cerveney et al. [68] evaluated the efficacy of phage (used locally and systemically) against the Gram 
negative bacterium Vibrio vulnificus (causes septicemia after ingestion of contaminated oysters and 
necrotising fasciitis in contaminated wounds) in an iron-dextran-treated mouse model. Bacteria were 
injected subcutaneously whereas phage were injected intravenously. A high phage dose (10
8
 PFU) 
was given (the animal was subcutaneously given a dose of 10
6
 CFU of a highly virulent clinical isolate 
of the bacterium to create a skin lesion) and shown to reduce the bacterial burden of the lesion and in 
the bacterial CFU in the liver (14 h post infection). Experiments with delayed treatment (≥ 6 h) post 
infection showed lack of efficacy and resulted in failure. Dose response studies with animals infected 
with 10
3
 CFU of bacteria and immediately given either 10
4
, 10
6
 or 10
8
 PFU of phage showed only the 
higher concentration of phage dose at 10
8
 PFU afforded significant protection to the treated mice. The 
need for high phage dosages was attributed to the short doubling time of the bacterium (45 min) 
which resulted in a high growth rate of bacteria post infection. The study also evaluated the half-life of 
phage (2.2 h at 10
8
 PFU) injected intravenously and found that phage concentrations in blood rapidly 
decreased due to clearance by the reticuloendothelial system. Phage are known to induce antibodies 
aiding their removal from circulation as well as neutralising their interaction with bacteria [30,42,89].  
 
Matsuzaki et al. [71] showed dose dependent pharmacodynamics using concomitant intraperitoneal 
injection of S. aureus followed by phage (delivered within 60 min of bacterial inoculation) with high 
concentrations of phage observed in blood (at high phage doses 10
11
 PFU to treat 10
9
 CFU of S. 
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aureus) indicating in situ amplification of phage. In a rabbit model of wound infection induced by S. 
aureus, Wills et al. [33] used a high dose of phage (10
9
 PFU, delivered subcutaneously) whilst 
simultaneously infecting with S. aureus (~10
8
 CFU) to show protection against abscess formation. The 
study also carried out a dose response study and showed that only at the highest phage dose was 
there an absence of abscess formation. The median area of abscess formation and the concentration 
of bacteria found in the abscess (CFU/ml) showed an inverse correlation with the dose of phage 
given. The effect of delaying treatment (by giving a high phage dose (10
9
 PFU) 6h, 12h and 24h after 
bacterial infection) resulted in abscess formation in all animals.  
 
McVay et al. [34] in a mouse burn wound model compared intramuscular, subcutaneous and 
intraperitoneal routes of phage delivery using a cocktail of Pseudomonas aeruginosa phage. Phage 
administered by the intraperitoneal route (~10
8
 PFU) afforded better protection against P. aeruginosa 
infection (~10
2
 CFU injected subcutaneously at the burn site) with higher concentrations of phage 
found in the blood, spleen and liver of animals. Phage resistant mutants were not found even in 
animals that had died. Intraperitoneal delivery of phage was found to result in delivery of higher phage 
dose, delivered earlier into the blood and other tissues, and delivered for a more sustained period of 
time.  
 
 
Capparelli et al. [29] intravenously infected mice with S. aureus (dose, 10
8
 CFU/mouse) followed by 
immediate intravenous injection of phage (10
7
, 10
8
 or 10
9
 PFU/mouse). All the mice in the control 
group (infected but not treated with phage) and those treated with the lowest phage dose (10
7
 
PFU/mouse) died within 4 days (10/10 mice). The mice treated with the intermediate dose (10
8
 
PFU/mouse) were only partially protected (2/5 mice survived) whilst mice treated with the highest 
dose (10
9
 PFU/mouse) all survived (5/5 survived). 4 days after phage injection, high concentrations of 
bacteria (in kidney, heart, spleen and lung) were recorded for the untreated controls whereas no 
bacteria were found in the same organs for mice treated with 10
9
 PFU/mouse. Lack of phage 
amplification in blood (attributed to a replication threshold) was in all likelihood down to the low 
concentrations of bacteria in blood making it difficult to accurately monitor phage amplification under 
such conditions. At low levels of systemic infection (S. aureus dose 10
6
 CFU/mouse) a 10 day delay 
in phage therapy (10
9
 PFU/mouse) cleared S. aureus infection in the animals. Capparelli et al. [29] 
also evaluated the efficacy of phage therapy for local S. aureus infections (subcutaneous injection of 
bacteria and phage ). Concomitant injection of phage prevented formation of abscess in the mice. 
Delayed phage treatment (phage administration 4 days after onset of infection) did not prevent 
abscess formation. There was a reduction in the bacterial load in the abscess and the weight of the 
abscess when multiple injections (4 injections per day) were used. Repeated doses were found to be 
more effective than a single dose in reducing the bacterial load in the abscess and the weight of the 
abscess. S. aureus can adopt an intracellular lifestyle. Capparelli et al. [29] also evaluated the efficacy 
of phage activity in a S. aureus intracellular infection mouse peritoneal macrophage cell line model. 
Phage were not able to penetrate the macrophage and kill the intracellular S. aureus. Using a Trojan 
horse approach, S. aureus infected with phage were able to access the intracellular compartment of 
the macrophage and kill S. aureus cells residing within. This study suggests the possibility of 
encapsulating phage in systems that may facilitate access to intracellular compartments where 
infecting bacteria may be targeted (more on this later in the section on encapsulation of phage in 
liposomes to target intracellular pathogenic bacteria).  
  
Oral phage delivery (animal studies) 
Animal studies using oral delivery of bacteriophage have focused on acute gastrointestinal infections 
(Table 1). The main concern here is phage inactivation due to the acidic and proteolytic environment 
of the stomach. The use of antacids e.g. calcium carbonate or bicarbonate prior to infection challenge 
or with phage delivery in order to neutralise the stomach acidity has been common practice in a 
number of studies [23,58,64,76,78]. A few studies have employed encapsulation of phage in polymer 
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or liposome encapsulation systems [57,75,77,78]. Colom et al. [77] showed that encapsulation of 
phage in liposomes resulted in significantly longer periods of phage retention (several days longer) in 
the caecum of chickens and lower number of bacteria colonising the gut.  
 
Chibani-Chennoufi et al. [83] showed survival of T4-like E. coli phage through the gastrointestinal tract 
of mice when added to drinking water. The minimal oral dose for consistent fecal recovery was 10
4
 
PFU/ml of drinking water. E. coli infected mice showed 10
5
 fold amplification of phage with 
concomitant drop in fecal E. coli counts from 10
8
 to 10
4
 CFU/ml. However, phage sensitive E. coli 
concentration recovered post-treatment even when residual high fecal phage titres were present, 
suggesting phage sensitive E. coli were able to replicate in the gut and that the concentration of 
phage present in the gut was not high enough to eliminate the E coli. The authors suggested sites in 
the gut where E. coli may be protected from the phage (cells growing as microcolonies in the mucin 
layer). Other studies have also reported an initial reduction in faecal shedding followed by recovery of 
bacterial numbers [64,73,74]. 
 
Tanji et al. [64] used a chemostat (in vitro studies) to investigate the dose and frequency of phage 
administration on phage-E. coli population dynamics. The chemostat experiments suggested repeated 
high doses of phage were needed to keep the E. coli concentration in check. The results informed 
phage therapy in mice where E. coli was orally administered (dose 10
9
 CFU/mouse) using a plastic 
sonde directly into the stomach followed 2 days later with phage cocktail delivery to the stomach in a 
similar manner (single dose of 10
8
 PFU/mouse or 10
10
 PFU/mouse or repeated daily doses of 10
10
 
PFU/mouse). Daily administration of phage resulted in a stable concentration of phage in the faeces 
and significant reduction in the E. coli concentration in the faeces. A cocktail containing three phage 
was employed however, the concentration of phage in the faeces suggested one phage dominated 
and was present at a significantly higher concentration in comparison with the other two (indicating 
differences in the pharmacodynamics of the three phage). Nine days after the start of phage therapy 
with daily administration of phage, no E. coli were detected in the lower small intestine and the colon 
of treated mice. A number of studies have used repeated dosing of phage and shown reduction in 
intestinal colonisation with bacteria [57,76–80]. This study stands out as one of very few where 
elimination of E. coli was observed for treatment of gastrointestinal infections. 
 
Wagenaar et al. [73] evaluated the prophylactic or therapeutic efficacy of phage treatment for control 
of Campylobacter jejuni (C. jejuni is an important human pathogen and is the most common cause of 
bacterial gastroenteritis worldwide) colonization in young broiler chickens. A modest 1-log reduction in 
bacterial CFU counts (~10
9
 CFU/g faeces) was observed in both the prevention and the therapeutic 
groups compared with the control group (not given phage ). Phage selection was on the basis of 
activity across a wide range of C. jejuni strains.  
 
Watanabe et al. [70] investigated the efficacy of phage therapy using a murine model of gut-derived 
sepsis caused by P. aeruginosa (resembling the clinical pathophysiology of septicemia in humans). 
Administration of cyclophosphamide (to suppress the immune system) and ampicillin (to disrupt the 
gut microflora) was used before oral inoculation with P. aeruginosa to achieve gut-derived sepsis. 
Intestinal overgrowth in the gut resulted in P. aeruginosa crossing the gastrointestinal mucosal barrier 
by bacterial translocation and spreading systemically in the mice. Timing of phage treatment was 
found to influence the efficacy of phage therapy. Mice treated with a high dose of phage 1 day post 
infection with P. aeruginosa showed improved survival rates over controls (mice not treated with 
phage). Average numbers of viable bacteria in blood, liver, spleen and mesenteric lymph nodes were 
significantly lower in phage treated mice compared with controls. Faecal counts were also lower in 
phage treated mice as were cytokine levels in serum and liver. Compared to oral administration, 
intravenous and intraperitoneal administrations of phage were found to result in better outcomes. The 
infectious dose was 10
6
 CFU/mouse with phage dose of 10
10
 PFU/mouse. Only simultaneous 
intraperitoneal administration of phage and bacteria resulted in improved mice survival.  
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Andreatti et al. [74] showed short term (24h after infection) reduction in Salmonella enterica detection 
(dose ~10
4
 CFU/chick) from caecal tonsils following phage administration (phage cocktail containing 
45 different phage administered using oral gavage, 10
8
 PFU/chick). However, no significant 
differences were observed between the phage treated and the control groups after 48h. The cocktail 
used wasn’t sufficiently well characterised in terms of individual phage concentrations and the kinetics 
of individual phage binding and their lytic activity; a recurring theme in the reading of literature in this 
area.  
 
Stanford et al. [75] encapsulated E. coli phage in a commercial pH responsive methacrylate polymer 
using a spray drying process (a 1 log reduction in activity due to spray drying was noted). Oral 
inoculation of 10
11
 CFU/steer of a five strain mixture of E. coli O157:H7 was followed either by 
encapsulated phage given as a single oral bolus (10
10
 PFU/steer) or mixed-in with feed (10
11
 
PFU/steer). Higher concentration of faecal shedding of phage (2-log higher) was noted for 
encapsulated phage given as part of the feed rather than bolus suggesting differences in in situ phage 
concentrations. Phage were shown to replicate in situ over a period in excess of ten days following 
treatment and continued to be shed 42 days post treatment (albeit at lower concentrations in 
comparison with the first ten days) however, no significant differences in reduction in E. coli shedding 
was observed between the phage treated steer and the controls. Insufficient understanding of the in 
vivo pharmacodynamics of the phage against the E. coli strains may have resulted in poor outcomes 
of phage therapy.  
 
To address the issue of human gastroenteritis caused by E. coli transmitted through farm animals, 
meat and poultry Abdulamir et al. [57] studied the effect of a cocktail of 140 lytic E. coli specific phage 
encapsulated using a hydroxypropyl methylcellulose (HPMC) based enteric coating. The capsules 
(ZeinPharma Germany, GmbH, Germany) encapsulating the 140 E. coli specific phage were 
administered orally in rats. A concentration of 10
7
 PFU/ml phage suspended in an aqueous solution of 
sodium bicarbonate and an injectable master mix in lambda buffer were compared with HPMC 
capsules carrying the phage cocktail in lambda buffer. HPMC encapsulated phage were found to give 
better results with a reduction in E. coli shedding of up to 4-log.  
 
Nale et al. [55] used a hamster model for the oral delivery of either single or a mixture of phage 
against Clostridium difficile. A hamster model of acute C. difficile infection (CDI) was used. The model 
reflected some of the clinical features of CDI including toxin-mediated diarrhoea and tissue pathology. 
Animals were given sodium bicarbonate orogastrically to reduce stomach acidity. Animals were 
infected with ~10
3
 CFU/hamster of spores and subsequently treated with ~10
8
 PFU/hamster of either 
a single phage or a cocktail of phage. The first dose was given at the time of infection with further 
doses every 8 h until the scheduled end-point of 36 h (toxin production in untreated animals is limited 
up to this time point in the cecum and colon thereby allowing assessment of the effect of phage 
treatment on colonization in the absence of toxin related symptoms). At this time point, animals were 
culled and enumeration of total bacterial load (spores and vegetative cells) in the cecum and colon 
was undertaken. Phage treatment with certain combination of phage mixtures was shown to reduce 
bacterial load in the cecum and colon however, results were variable. This variability was attributed to 
the ratio of phage to bacteria present at various locations in the cecum and colon during the initial 
phase of bacterial outgrowth. In a separate experiment using the earlier protocol but continuing 
regular 8h phage treatments delayed onset of symptoms by 33 h (due to toxin production) in phage 
treated animals compared to untreated animals was observed. Complete protection was not achieved. 
The amount of phage delivered to the cecum or colon was not quantified however, high titres of phage 
10
7
 PFU/ml were recovered from the cecum and colon. 
 
Recently Colom et al. [77] used a cocktail of three Salmonella phage individually encapsulated in 
cationic liposomes to treat Salmonella infection in commercial broilers under farm-like conditions. 
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Bacteriophage retention in the chicken caecum was investigated by giving an oral dose of phage (10
10
 
PFU/chicken) of either free phage (1:1:1 mixture of the three phage 20, 78 and 87) or liposome 
encapsulated phage cocktail to 63 1-day old chickens. Caecum samples collected from euthanized 
animals showed significantly higher numbers of chickens treated with encapsulated phage had phage 
in their caecum 48h and 72h later. Bacteriophage therapy against Salmonella was evaluated over 17 
days in chickens orally administered either the free phage cocktail or encapsulated phage cocktail 
(bacterial dose at day 0: 10
7
 CFU/chicken, phage dose 10
10
 PFU/chicken). Oral doses of phage were 
administered daily for 9 days (from day -1 to day 7 after Salmonella infection). Over the course of 
daily phage therapy (days 1, 3, 6) both groups receiving phage treatment showed lower (~ 3 log 
reduction) Salmonella concentration in the cecum compared with the control group. Once daily phage 
treatment had stopped (day 8 onwards), Salmonella concentration in the free phage treated group 
returned to levels similar to the control group. However, the liposome encapsulated phage treated 
group continued to show lower Salmonella concentration in the cecum compared with the control 
group up to day 15. Salmonella infection was not eradicated by either treatment which was attributed 
to high initial Salmonella concentration in the cecum (10
6
 CFU/g of cecum), which was considered 
higher than naturally occurring levels. 
 
In a separate study, Colom et al. [78] used a cocktail of three Salmonella phage individually 
encapsulated in alginate microparticles containing CaCO3 to treat Salmonella infection in commercial 
broilers under farm-like conditions. Bacteriophage retention in the chicken caecum was investigated 
by giving an oral dose of phage (10
10
 PFU/chicken) of either free phage (1:1:1 mixture of the three 
phage 20, 78 and 87) or alginate/ CaCO3 encapsulated phage cocktail to 63 1-day old chickens. 
Caecum samples collected from euthanized animals showed significantly higher numbers of chickens 
treated with encapsulated phage had phage in their caecum 48h and 72h later. Bacteriophage 
therapy against Salmonella was evaluated over 17 days in chickens orally administered either the free 
phage cocktail or encapsulated phage cocktail (bacterial dose of day 0: 10
7
 CFU/chicken, phage dose 
10
10
 PFU/chicken). Oral doses of phage were administered daily for 9 days (from day -1 to day 7 after 
Salmonella infection). Over the 15 days, a significant reduction (between 2 log and 3 log) in 
Salmonella concentration was noted for the group treated with encapsulated phage. At days 8, 10 and 
15 the encapsulated phage treated group had lower Salmonella concentration compared with the free 
phage treated group showing better therapy outcomes using the encapsulated phage . The 
mucoadhesiveness of the microparticles and the slow sustained release kinetics were thought to be 
important factors in explaining these results. Similar concentration levels of phage were noted in the 
caecum for both encapsulated and free phage (~ 10
3
 - 10
4
 PFU/g). Phage persisted in the caecum 
even after phage treatment was stopped with higher phage concentrations noted for the free phage 
treated animals. Salmonella infection was not eradicated by either treatment. The authors reported 
that they did not find any phage resistant bacteria in the phage treated groups. Hence the persistence 
of Salmonella infection was not attributed to phage resistant mutants.  
 
A different study using alginate microencapsulated Salmonella phage to treat pigs [59] showed that 
co-administration of Salmonella with a phage cocktail resulted in reduction in pig intestinal Salmonella 
concentration (~2 log reduction). Yen et al. [58] recently reported studies with mice and rabbits on the 
prophylactic effect of phage therapy to treat cholera. Oral administration of a cocktail of three V. 
cholera lytic phage up to 24 h prior to infection with V. cholera reduced colonization and cholera-like 
diarrhoea. Complete elimination of bacteria was observed at short prophylaxis times (3h), high phage 
dose (10
6
-10
7
 PFU/mouse) and low bacterial infection dose (10
5
 CFU/mouse). Phage administration 
in negative controls (i.e. not inoculated with bacteria) showed a significant drop in phage titre (3 log 
reduction in mice) 12 h following phage treatment, indicating phage elimination by the host.  
 
Pulmonary delivery (animal studies) 
Pulmonary delivery of phage has been achieved using a variety of methods including nasal instillation 
[26–28,42], aerosolization of liquids using a nebulizer [90,91] and intraperitoneal injection [31,32]. 
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Carmody et al. [42] found intraperitoneal delivery of phage resulted in reduction in an acute lung 
infection in mice compared with nasal instillation whereas Oliveira et al. [92] found intramuscular 
injection better than oral administration or using a spray.  
 
The dose of phage, concentration of bacteria and the timing of phage therapy were found to have a 
significant impact on phage therapy outcomes. In most cases delivering high doses of phage 
immediately or soon after inoculation of lungs with bacteria resulted in better outcomes [26,28,32]. 
Singla et al. [39] compared treatment of induced acute K. pneumonia infection in mice with free phage 
versus liposome encapsulated phage and showed that high dose of encapsulated phage gave better 
outcomes given up to 48 h prior to infection. A number of studies reported in situ amplification of 
phage [26,28,39]. Phage were rapidly cleared from the lungs of mice [28] hence high phage dose was 
need for prophylactic treatment 24 h prior to bacteria inoculation [26]. Effective phage therapy 
reduced the host inflammatory response [26,28,39].  
 
Phage for treating respiratory infections caused by P. aeruginosa, B. cenocepacia, E. coli and K. 
pneumonia are available. Efficacy of phage activity against clinical strains obtained from CF sputum 
and in relatively early stage biofilms has been shown [27,39]. Phage with lytic activity have been 
shown to possess hydrolases that degrade bacterial exopolysaccharides. Animal studies have shown 
that a number of phage delivery routes are effective for phage delivery to treat acute lung infections. 
However, further work needs to be done to show the efficacy of phage therapy in chronic infections 
against more mature biofilms containing well established polymicrobial communities in both in vitro 
and in vivo systems.   
 
Oliveira et al. [92] evaluated the effect of the route of administration (oral, direct spray on beaks and 
intramuscular injection) and the concentration of phage in the dose (10
6
, 10
7
 and 10
8
 PFU/chicken) in 
the dissemination of 3 lytic E. coli phage in the organs of chickens (lungs, liver, duodenum and 
spleen). The focus of the study was on controlling avian respiratory infections. Administration of 
phage using intramuscular injection was found to be the best means of ensuring phage dissemination 
in all tissues (including lungs). In the work by Oliveira et al. [92], aerosol spray administration (details 
regarding the spray generation were not given) allowed phage to be directly delivered to the lungs. 
Sufficient details regarding the formulation of phage for spray dose were not given, e.g. whether the 
spray droplet size distribution was suitable to aid droplet distribution in the lower respiratory tract. The 
phage type, administration route and dose delivered were all found to affect the distribution of phage 
in the animal tissues. Phage were rapidly cleared from the organs 10 h after administration.  
 
Huff et al. [90] determined the efficacy of aerosol administration (using an atomising nozzle and 
exposing the birds to the aerosol in a closed chamber resulting in uptake by inhalation) of a cocktail 
containing two bacteriophage (isolated against avian pathogenic E. coli) to prevent an E. coli 
respiratory tract infection in broiler chickens. A severe dose of 10
4
 CFU/chicken (age 1 week) followed 
by a cocktail of phage (a mixture of two phage at 10
7
:10
8
 PFU/chicken) resulted in reduction in 
observed mortality (at age 3 weeks) compared with untreated controls. The dose of phage was found 
to be important with lower concentrations of aerosolized phage affording worse protection. The timing 
of phage administration was also evaluated with phage treatment immediately following E. coli 
infection showing positive efficacy results. However, results were mixed when phage were 
administered prior to or 3 days following E. coli challenge. Bacteria were cultured from swabs of liver 
and air sacs but data on phage titres from the tissue samples were not given.  
 
Carmody et al. [42] investigated the therapeutic potential of bacteriophage in an in vivo mouse model 
of acute B. cenocepacia pulmonary infection. Carmody et al. [42] compared intranasal inhalation of 
bacteriophage with intraperitoneal injection of phage . 9 to 12 week old mice were infected with 10
7
 or 
10
8
 CFU B. cenocepacia (via tracheotomy). 24 h after infection, mice were treated with either 
intranasal inhalation (spray details not given) or intraperitoneal injection of phage suspended in buffer 
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(100 times higher dose of phage with respect to the bacterial dose was given). 48 h after phage 
treatment, mice were euthanized and lung tissue samples were analysed for B. cenocepacia and 
phage. Mice treated with phage delivered via intraperitoneal injection had significantly lower lung 
bacterial counts compared with untreated control mice 48 h after treatment. The phage concentration 
in the lungs of mice was not statistically significant from mock infected mice with similar dose of 
intraperitoneal treated phage. The intranasal treatment did not result in a statistically significant 
reduction in lung bacterial counts however phage had amplified in the lungs and were present at 
concentrations above those in mock infected mice with similar dose of inhaled phage. 24 h after 
infection (but before phage treatment), bacteria were primarily found in lung parenchyma in 
peribronchiolar and perivascular areas, occasionally co-localized with alveolar macrophage. Relatively 
few bacteria were found in the airway lumen. 72 h after infection (without phage treatment), bacteria 
were found in microcolonies in lung parenchyma. The concentration of phage in lungs of mice treated 
intranasally was 2 log higher in comparison with intraperitoneal treated mice. Intranasally 
administered phage were found co-localised with alveolar macrophages 48 h after treatment. This 
suggested that phage delivered via pulmonary delivery were sequestered by lung macrophage and 
therefore may be unavailable to kill bacteria found in the lung parenchyma. Inhaled phage did 
replicate in bacteria as the titres were found to be higher compared with the control group. Phage may 
have been able to replicate in bacteria taken-up by the macrophage. The phage in the macrophage 
remained viable as determined by the high phage titres. In intraperitoneally treated mice, phage were 
found in vascular and perivascular areas and alveolar septa where phage were found co-localized 
with degraded bacteria. Results from the study indicated better access of phage delivered 
intraperitoneally via systemic circulation to bacteria than those delivered via pulmonary delivery. The 
site of greatest bacterial killing may have been within the lung parenchyma rather than the airway 
lumen. Phage delivered via the airway may not have been able to effectively penetrate the respiratory 
epithelium where bacteria may have translocated from the lumen to the lung interstitium. The lower 
concentration of phage in the lung following intraperitoneal delivery was attributed to a rapid decrease 
in bacterial density and clearance of phage thereafter in the absence of sufficient bacterial hosts.  
 
Semler et al. [91] found aerosol delivery of B. cenocepacia phage in a mouse lung infection model to 
be an effective means of phage delivery resulting in reduction in B. cenocepacia concentration over a 
three day period post-infection. They also evaluated intraperitoneal delivery of B. cenocepacia phage 
which resulted in higher concentrations of phage delivered to the lung supporting the findings of 
Carmody et al. [42] that intraperitoneal delivery of phage allows phage to access the lung. There was 
however a discrepancy between the results of Semler et al. [91] and Carmody et al. [42] with regard 
reduction in mouse lung bacteria concentrations for phage delivered using the intraperitoneal route. 
This may be explained by low concentrations of bacteria present in the lung for experiments carried 
out by Semler et al. [91] which may have resulted in poor in situ phage amplification.  
 
Debarbieux et al. [26] evaluated pulmonary phage therapy using a fluorescently labelled P. 
aeruginosa strain (to monitor in real time the spatial and temporal development of infection) in an 
acute mouse lung infection model. The infectious dose was 10
7
 CFU/mouse. In preventive 
experiments, phage were given intranasally 24h before infection. Page lysates were simply purified 
using caesium chloride ultracentrifugation and then suspended in phosphate buffered saline. 
Untreated mice died within 48 h of infection. Mice treated with a phage to bacterium ratio of 1:10 died 
within 5 days after infection. Mice treated with a higher phage to bacterium ratio 1:1 (80-100%) and 
10:1 (100%) survived until the end of the experiment (12 days post infection). Subsequent 
experiments were carried out using the higher phage dose i.e. phage to bacterium ratio of 10:1. 
Phage were administered 2 h post infection. Within 6h post infection differences were observed in the 
amount of luminescent bacteria in the lungs of the infected mice suggested rapid killing by the phage. 
After 24h untreated mice were either dead or showed high levels of luminescence whereas phage 
treated mice showed no or weak spots of light with tissue cultures showing bacterial load of 10
8
 
CFU/ml in untreated mice versus 10
2
 CFU/ml in phage treated mice at 24h post infection. Phage 
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concentrations in bronchiolar lavage fluid were lower in uninfected controls (10
6
 PFU/ml) versus 
infected and phage treated mice (10
7
 PFU/ml) indicating phage amplification within the infected lungs. 
Measurement of inflammatory cytokines IL-6 and TNF-alpha indicated attenuation of the host 
inflammatory response due to phage treatment. Delaying phage treatment by 2h, 4h and 6h post 
infection resulted in all mice surviving after 24h (treated with phage 2h post infection) but only 75% of 
mice surviving following phage treatment 4h and 6h post infection. At 72h post infection survival was 
as follows 100% (2h delay), 75% (4h delay) and 25% (6h delay). Phages were seen to remain 
effective in mice 24h following treatment. Infection of mice 24h post phage treatment (intranasal 
administration of 10
8
 phage /mouse: 10
7
 CFU/mouse) resulted in 100% of mice surviving 16 days post 
infection whereas all untreated mice had died. Non-invasive bioluminescence data suggested that 
rapid bacterial replication kinetics was an important factor in arresting infection by early administration 
of phage when the bacteria are also highly susceptible to phage infection. High dose of phages 
administered early during the onset of infection rapidly reduced bacterial numbers and the associated 
inflammatory response in the host.  
 
Alemayehu et al. (2012) compared phage therapy efficacy in a murine model using both mucoid and 
non-mucoid P. aeruginosa strains isolated from CF patients. Lungs of 6- to 8- week old mice were 
infected intranasally with lux-tagged Pseudomonas (dose 10
6
 CFU/mouse). 2h following infection a 
binary mixture of phage (podovirus and myovirus) was delivered intranasally at a dose of 10
7
 
PFU/mouse. Phages were effective in reducing considerably the amount of bacteria associated 
bioluminescence in the first 6h period post infection.  
 
Morello et al. (2011) evaluated the efficacy of phage treatment in a mouse lung-infection model (a 
dose of 10
6
 CFU/mouse resulted in animal death 2 days following infection) against a multidrug 
resistant P. aeruginosa mucoid strain isolated from a cystic fibrosis patient. Within 20h post infection, 
bacteria had multiplied in the lungs by 2-log compared with the initial dose (found in broncho-alveolar 
lavages). A dose dependent curative effect was observed when phage (dose 10
6
 PFU/mouse or 10
7
 
PFU/mouse was given intranasally 2h post infection). 20h post infection bacteria were detected in 
macrophage, alveolae and extracellular spaces of lungs from animals not treated with phage. Phage 
treatment resulted in lower concentrations of bacteria, high concentrations of phage (suggesting in 
situ amplification) and low concentration of markers of host immune response (cytokines and lactate 
dehydrogenase) with histological examination of lung tissue samples indicating less severe damage 
to lung tissues for the phage treated mice. Uninfected mice given phage intranasally cleared these at 
the rate of 0.5 log per day. Phage given 4 days prior to mice being given an infective dose of bacteria 
needed high preventive phage doses (10
8
 PFU/mouse) to achieve 100% survival.  
 
The use of bacteriophage as a therapeutic strategy to fight K. pneumoniae infection has previously 
been tested; a murine model of infection could be cleared [32]. However, in this study (as in other 
animal studies reviewed above), clearance of infection only occurred when bacteriophage were 
administered immediately after K. pneumoniae infection which limits the potential of phage therapy for 
clinical use.  
 
Singla et al. [31] used liposome encapsulation of the lytic K. pneumoniae bacteriophage (belonging to 
the Podoviridae family). They investigated treatment efficacy of liposome-encapsulated phage 
compared with free phage, to treat established K. pneumoniae infection in a murine pneumonia 
model. Delay in phage treatment administered via intraperitoneal injection (6h, 24h and 48h) post 
intranasal administration of K. pneumonia was investigated. Free phage administration 6h post 
administration of K. pneumonia was shown to result in complete elimination of K. pneumonia from 
lung samples (this was not the case for the 24h (~ 2 log reduction in CFU noted) and 48h (CFU levels 
similar to untreated positive controls) treated animals) delay is phage treatments. Phage were 
observed in the vascular and perivascular areas and along alveolar septa; similar results were 
reported by other researchers [42]. Phages were observed in lungs for longer (up to ~ 3 - 4 days) for 
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animals infected with K. pneumonia compared with negative controls. Phage amplification was noted 
in infected animals treated with free phage. Animals treated with liposome encapsulated phage 6h 
(infection cleared in 24h post treatment), 24h (infection cleared in 24h post treatment), 48h (reduction 
in CFU) and 72h (reduction in CFU) after K. pneumonia infection showed variable levels of efficacy of 
treatment. Earlier treatment was better than delaying treatment 48h or 72h. In the K. pneumonia 
mouse infection model, bacteria concentrations in control animals (untreated) was seen to peak at 
day 3 and fell significantly by day 5. Phage amplification in lung samples was noted for phage 
encapsulated liposome treated animals. Liposome entrapped phage persisted in lungs for 5 days post 
treatment. Prophylactic phage treatment (3h, 6h and 24h prior to intranasal K. pneumonia infection) 
was studied [31]. No significant therapeutic effect was observed for mice treated with free phage 24h 
prior to infection. The 3h and 6h treatment resulted in absence of infection. For phage encapsulated in 
liposomes no infection developed when mice were treated 6h, 24h and 48h prior to administration of 
infection suggesting encapsulation had a beneficial prophylactic therapeutic effect due to retention of 
the phage at therapeutic concentrations in the lung. 
 
Singla et al. [31] showed evidence of reduction in levels of pro-inflammatory cytokines IL-6 and TNF-α 
in free phage (0h and 6h prior to intranasal bacterial inoculation) and liposome treated animals (24h 
and 48h prior to intranasal bacterial inoculation). Debarbieux et al. [26] showed reduction in host 
inflammatory response due to reduction in the number of bacteria upon phage treatment.  
 
Although the majority of K. pneumoniae bacilli during infection are thought to be extracellular, it is 
recognised that K. pneumoniae can survive within macrophage and epithelial cells [93,94]. Liposome 
encapsulation may enhance access of phage to intracellular K. pneumonia. Using an ex vivo model of 
cultured murine peritoneal macrophage infected with K. pneumonia, Singla et al. [95] showed that 
cationic liposome encapsulated phage were able to kill greater numbers (~ 95%) of intracellular K. 
pneumonia compared with free phage (~ 20%). A potential limitation of phage therapy for treatment of 
infection is the development of phage -neutralizing antibodies which may result in reduction of the 
concentration of phage at the site of infection or in systemic circulation [30]. Singla et al. [95] 
demonstrated using ex vivo experiments that liposome encapsulation was effective at completely 
protecting K. pneumonia phage from the neutralizing effect of murine antibodies. Free phage were 
inactivated by serum antibodies raised against the phage in mice. Liposome encapsulated phage 
were able to inactivate K. pneumonia following 3h exposure to mouse serum containing antibodies.  
 
Phage therapy for Chronic Infections 
Results of animal studies (discussed above) relate to acute, rapidly progressive infections. In chronic 
infections, bacterial populations may have a greater diversity of bacterial strains as polymicrobial 
colonies encased within biofilms with significant bacterial populations maintained over long periods of 
time, years even decades. Although a measureable specific immune response to the presence of the 
antigens expressed by the infecting bacteria may be present, however, on its own, the host may be 
unable to clear the infection.  
 
Alemayehu et al. [27] investigated the ability of phage to penetrate and kill Pseudomonas cells 
growing as biofilms on the surface of a layer of human lung cystic fibrosis bronchial epithelial cells. 
Phage applied to 24 h old biofilms (bacteria concentration ~10
7
 CFU/well; phage dose ~10
8
 PFU/well) 
were able to increase phage numbers by replicating in situ whilst killing the resident Pseudomonas (2-
log reduction in observed bioluminescence and 3- to 4-log reduction in cell concentration after 24h 
incubation of phage with cells). It took longer to clear Pseudomonas grown in biofilms in comparison 
with planktonic cells in the lung model. Singla et al. [95] evaluated phage activity against young (4 day 
old) and more mature (7 day old) K. pneumonia biofilms. Both free phage and liposome encapsulated 
phage showed similar levels of antimicrobial activity (~ 2 log reduction in CFUs) in the 4 day old 
biofilm model compared with the antibiotic amikacin. For 7 day old biofilms the effect was less marked 
(~ 1 log reduction). 
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Cocktails of phage covering multiple species and having the correct host range for different strains 
may be needed to facilitate clearance of chronic infections. Examples of such chronic infections 
include infections in cystic fibrosis (P. aeruginosa) and tuberculosis (M. Tuberculosis). Having suitably 
diagnosed the polymicrobial constitution of the infection causing bacteria, tailored phage formulations 
would need to be prepared and administered. Phage banks with well characterised phage lines with 
long shelf life would be needed in order to prepare such formulated phage cocktails and supplied for 
clinical use. The challenge here is delivery of precise concentrations of formulated phage cocktails at 
the site of infection e.g. for cystic fibrosis, which may require the phage to penetrate biofilms to gain 
access to the bacteria. Furthermore the phage would need to be phagocytosed into macrophage to 
target M. tuberculosis cells present in granulomas which poses an additional challenge.  
 
Phage therapy Case Studies with Humans and Recent Clinical Trials 
There are relatively few recent published randomised control trial studies on the therapeutic use of 
phage involving humans. Typically these tend to be case studies [96] however, recently two small 
randomised controlled trials have been undertaken [35,97]. The formulations used for these trials tend 
to be simple phage lysates that have been purified using crude laboratory methods including 
centrifugation, microfiltration, ultracentrifugation and in some instances endotoxin removal through 
affinity chromatography [98]. Phage cocktails used for the trials were simple suspensions in buffer 
without microencapsulation. The titre of phage s used was typically low and reliant on in situ 
amplification which may have resulted in therapy failure in at least one of the studies [35].  
 
Wright et al. [97] conducted a small (24 patients) randomised (two groups of 12), double blind Phase 
I/II clinical trial to evaluate the safety and efficacy of a therapeutic phage preparation against chronic 
otitis due to antibiotic resistant Pseudomonas aeruginosa infection. Each 0.2 mL dose contained 10
5
 
PFU/ml each of six bacteriophages suspended in 10% glycerol in phosphate-buffered saline and was 
applied to the infected ear using a standard 1 mL syringe equipped with a 27 gauge spinal needle. 
Patients re-visited the clinic on days 7, 21 and 42 days following treatment. Patient inclusion criteria 
included checking that the P. aeruginosa strain causing infection were susceptible to at least one 
phage in the therapeutic cocktail. Bacteriophage amplification (~ 2 log) was noted for bacteriophages 
in human subjects under trial conditions [97]. There were no reported side effects and no evidence of 
local or systemic toxicity due to phage therapy. Phage therapy was shown to result in a modest 
reduction (from the baseline) in median P. aeruginosa counts. Results were not overwhelmingly 
conclusive. In cases where infection was treated phage counts decreased to below the limit of 
detection. At day 42, 3 out of 12 patients in both the phage therapy group and the placebo group had 
levels of P. aeruginosa below the limit of detection. High levels of P. aeruginosa were present in 
patients ~ 10
9
 CFU/g. 
 
A recent randomized phage therapy trial to reduce E. coli associated diarrhoea in children (6-24 
month old males) failed to improve diarrhoea outcomes. This was attributed to low intestinal E coli 
concentration resulting in lack of significant phage amplification in vivo [35]. Half of the patients 
contained phage susceptible E coli in stool samples however, the stool CFU titres were low (median 
titre 10
5
 CFU/g stool). Phage-bacteria pharmacodynamics dictates that conditions where there is a 
low in situ bacterium concentration are not conducive to significant phage amplification. Phage 
cocktails used in the study were given without antacid and were not protected from the stomach 
acidity by encapsulation hence phage titres reaching the site of infection may have been low. Rapid 
elimination of the phage from the host may also have further lowered the efficacy of the treatment. 
 
Fish et al. [96] recently published results of six case series where bacteriophage treatment of 
intransigent diabetic toe ulcers had been successfully treated. The study used a commercially 
available (Eliava Biopreparation, Tbilisi, Georgia) single lytic phage Sb-1 (broad host range against S. 
aureus) in sterile solution (10ml per vial containing ~10
7
-10
8
 PFU/ml). Treatment involved standard 
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wound care, including weekly soft tissue debridement if necessary [96]. Phage preparation was 
applied topically by dripping the phage solution into the wound cavity; gauze soaked with phage 
solution (0.1 - 0.5 ml depending on ulcer volume) was packed into the cavity and the wound was 
wrapped with dry gauze. The actual dose given was variable depending on the size of the toe ulcer. 
The patient was instructed to leave the gauze in place for 48 h. The protocol was repeated weekly in a 
hospital-based wound setting until the ulcer became too small to pack. All six cases reported in the 
paper healed with an average time to heal of ~6 weeks.  
 
Merabishvili et al. [98] prepared a well-defined cocktail (designated BFC-1) of lytic phage (containing 
a mixture of three broad host range lytic phage ; two Myoviridae (against P. aeruginosa and S. 
aureus) and one Podoviridae (against P. aeruginosa)) designed for treatment of P. aeruginosa and S. 
aureus infections in burn wound patients as part of a pilot human clinical study. The cocktail contained 
10
9
 PFU/ml of each bacteriophage applied (application by spraying using a syringe with a spray 
adapter fitted at the end) in doses of 1 ml per 50 cm
2
 wound bed with the assumption that this would 
result in a ratio of phage to bacterium of 100:1. The cocktail formulation consisted of endotoxin free 
phage (pyrogenicity evaluated using a rabbit animal model) suspended in physiological buffer and 
stored at 2-8
◦
C in 3 ml ‘single use only’ vials. Stored at 4
◦
C, the phage suspension titre remained 
stable over 12 months. A safety trial on infected burn wounds of eight patients had shown no adverse 
events following application. No efficacy data was reported in the paper. However, a recent paper [99] 
presented results from the application of BFC-1 cocktail on colonized burn wounds in a small clinical 
trial (nine acute burn wound patients, 10 applications). Punch biopsies were taken to determine 
bacterial species identification and antibiotic susceptibility tests. 1 ml of BFC-1 solution was applied 
per 50 cm2 of burn wound area. The other half received standard treatment protocols. Patients also 
received systemic antibiotic treatment. Following BFC-1 treatment, the wound was covered with 
dressings, gauze and bandages according to standard treatment protocols. 2-5 h later, the burn 
wound was uncovered and two biopsies taken next to (within 2 cm) of the previous ones. Bacterial 
load determination of the biopsies was undertaken. Despite initial indications of wound colonisation or 
infection, bacterial cultures taken before and after treatment showed low levels of bacteria (in 8/10 
applications). In all cases bacterial load remained unchanged after BFC-1 applications as well as after 
standard treatment. The low bacterial load in the wound was attributed to topical and systemic 
antibiotic treatment of patients prior to enrolment of the patient in the study (which took 7 days from 
initial assessment of colonisation/infection with target pathogen). Rose et al. [99] found that the 
sprayed BFC-1 solution had a tendency to run off the burn wound. Better formulation e.g. as a gel or 
part of a dressing (e.g. with controlled release properties) was suggested for future trials.  
 
Summary 
For phage therapy to work, bacteriophage concentrations at the site of infection must be sufficiently 
high for significant in situ phage amplification to occur and as a result reduce the rate of replication of 
the infecting population of bacterium. The phages need to be delivered at the site of infection and they 
need to have access to replicating bacteria susceptible to phage infection. Even when susceptible 
bacterial concentrations are high at the site of infection, delivery of low concentrations of phage may 
not be sufficient to increase phage concentration rapidly enough to achieve rapid killing of bacteria. 
Self-amplification will not occur when concentrations of bacteria are low (Levin and Bull, 2004). In vivo 
reduction in phage concentration due to the host immune response or other mechanisms also needs 
consideration. Under these conditions, steady or frequent delivery of high concentrations of phage 
may be needed for successful phage therapy. Phage resistant populations are highly likely and 
require use of a number of phage strains that bind to different receptors thereby killing the mutant 
bacteria. Use of different phage strains for therapeutic use requires careful formulation of phages to 
retain phage stability such that viable phages at a sufficiently high concentration are present at the 
time of use. Rational design of micro- and nanocapsules loaded with precise dose of encapsulated 
phage in stimuli responsive controlled release systems could be engineered to do this. 
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Bacteriophage Encapsulation  
Developing formulations that incorporate bacteriophage for therapeutic applications requires an 
appreciation of the chemical and physical stresses phage may encounter both during processing as 
well as during storage once formulated. Phage inactivation and long term reduction in phage titre 
upon storage is highly undesirable. The physical and chemical properties of the formulation need 
careful consideration when selecting a technique for encapsulation. Accurate loading of phage per 
particle requires particle monodispersity which is rarely achieved in practice however, some 
techniques are considerably better than others (discussed below). The particle morphology should be 
without deformities and the particles shouldn’t aggregate or uncontrollably fuse together with material 
in the surrounding environment. A polymer or lipid may be used to coat an existing structure 
containing the phage, for example Murthy and Engelhardt [82] sprayed phage on dried skimmed milk 
and then encapsulated them in a lipid coating. Alternatively, phage may be incorporated in the 
formulation within the droplet which upon drying or crosslinking results in phage entrapment in the 
particle core. Depending on the technique used, polymer gelling may be part of the technique or it 
may be a process occurring downstream. There are many techniques and processes that may be 
used for stabilising, immobilising and encapsulating phage. The most common methods are spray-
drying, spray freeze drying, freeze drying, extrusion dripping methods, emulsion and polymerisation 
techniques. The literature focusing on phage encapsulation, formulation and storage stability is 
reviewed below and summary information is presented in Tables 2-4. 
 
Formulation of Bacteriophage for Preservation and Storage  
Phage are protein structures and they are therefore susceptible to factors known to denature proteins; 
these include exposure to organic solvents [100,101], high temperatures [102], pH [102,103], ionic 
strength [103], and, interfacial effects. Additionally, mechanical stresses during formulation or 
encapsulation including shear stresses during mixing and agitation, atomisation during spraying [104] 
and, desiccation stresses during drying [105], need careful consideration. Drying and lyophilization of 
bacteriophage with suitable carriers and bulking agents to improve storage life have been the focus of 
numerous studies (Table 2). A number of encapsulation techniques (reviewed further on) have been 
used, followed by drying [75] or incorporating solvent evaporation (e.g. during electrospinning, [106]) 
to improve phage storage. One of the most common and successful modes of long-term preservation 
of bacteriophage is storage at 4
◦
C in Trypticase Soy Agar and Brain Heart Infusion broth whereas 
storage at -80
◦
C requires 50% glycerol as a cryoprotectant [107] or freeze drying with excipients (e.g. 
sucrose or trehalose) as lyophilization and cryoprotectants [108,109]. Ackermann [109] observed that 
phage titres for one of the largest collections of tailed phages typically tended to drop by 1 log over 
the course of a year but then remained fairly stable (although there were many individual variations).  
 
Clark [107] working for the American Type Culture Collection (ATCC) evaluated storage stability of a 
wide variety of bacteriophages (16 in total) for long term preservation and distribution. Phage 
specimens were treated and stored for two years at room temperature and at 4
◦
C as (i) broth lysates; 
(ii) lysates diluted with 50% glycerol; (iii) saturating filter paper with lysate and then drying; (iv) freeze 
dried by mixing lysates with an equal volume of double strength skim milk (routine practice at that time 
at the ATCC). Phage titres measured immediately post processing indicated that freeze drying 
resulted in a significant loss of titre (between 1 log and 2 log reduction). However, freeze drying did 
produce stable phage titres over the course of 2 years when stored under refrigeration conditions. 
After two years, titre of phage in the broth lysates were found to be generally higher than those of 
glycerol or freeze dried preparations. Thermally dried preparations generally did not prove 
satisfactory. Preparations stored at 4
◦
C showed higher titres than those kept at room temperature. All 
titres declined with time regardless of the conditions of preservation.  
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Effect of thermal and environmental stresses on phage stability 
Phage may show different susceptibility to ingredients used in formulations. Knezevic et al. [103] 
examined the effects of environmental factors on adsorption and inactivation of four P. aeruginosa 
phage (one Podoviridae (designated ) and three Siphoviridae phage , (designated J-1, -1 and 
001A). Factors investigated included temperature (range 7-44
◦
C, exposure for 30min in SM buffer), 
pH ( pH1.5-pH9, at 37
◦
C for 30 min), phage neutralisation by exposure to carbohydrates and amino 
acids (potential phage receptor constituents; incubation at 37
◦
C for 30 min in SM buffer containing 
either glucose, rhamnose, mannose, galactose, glucosamine, glutamine or alanine), exposure to 
exopolysaccharides and lipopolysaccharides, silver nitrate (e.g. for combination therapy with phage ), 
povidone-iodine (for combination therapy) and exposure to serum of rats. All phage were completely 
inactivated after 30min exposure at pH1.5. Maximum viability was observed at pH7. Significant 
differences in susceptibility for the phage were observed at pH3, 5 and 9. Phage -1 and  were 
found to be less susceptible to low pH than J-1 and 001A. Survival at pH9 was higher than at pH5. 
Phage  was considerably neutralised by glucose, rhamnose, glucosamine, mannose and alanine. 
None of the phage survived at working silver nitrate concentrations of 0.3%. Phage  and 001A were 
highly sensitive to povidone-iodine; exposure for 30min to even the lowest concentration 0.5% 
completely inactivated them. For phage -1 and J-1 the PhI50 (i.e. concentration to achieve a 50% 
reduction in titre) concentration values were ~ 4%.  
 
Briers et al. [102] evaluated the stability of the structural peptidoglycan hydrolase gp181 of the P. 
aeruginosa Myoviridae bacteriophage KZ to temperature (range 25-90
◦
C), ionic strength (20-320 
mM) and pH(5-8). The protein is supposed to degrade the peptidoglycan layer locally during the 
infection process. Gradual loss of enzymatic activity due to thermal inactivation was observed from 
100% activity at 25
◦
C down to 0% at 70
◦
C when exposed for 60min and down to < 20% activity when 
exposed for 10 min to 90
◦
C. Optimal enzymatic activity at 25
◦
C was observed at pH6.2 and ionic 
strength 140mM with variation in pH and ionic strength in either direction resulting in loss of activity.  
 
Freeze Drying of Bacteriophage for Storage and Encapsulation 
Freeze drying (lyophilization) is routinely used in the pharmaceutical industry [110] to dry proteins , 
vaccines, peptides or colloidal carriers such as liposomes, nanoparticles and nanoemulsions [111]. 
Freeze drying is typically done from solution and involves a freezing step followed by a drying step. 
During the freezing step, the phage containing solution is cooled and ice crystals of pure water form 
resulting in concentration of the remaining liquid. This typically results in an increase in viscosity as 
well as osmolarity of the concentrated solution which inhibits further crystallization and eventually 
results in a frozen amorphous/crystalline phase. Preventing aggregation of bacteriophage and 
inactivation due to high osmotic pressure changes needs careful consideration here. At the end of the 
freezing stage, drying begins as a result of switching on a very low temperature condenser which 
draws water from the sample over time. A vacuum is also pulled to remove air which slows mass 
transfer to the condenser. A primary drying stage results in direct sublimation of the ice crystals, and 
remaining adsorbed water is removed in a secondary drying phase. In the freeze-dried state, the rate 
constants of most chemical and physical degradation reactions are dramatically reduced thereby 
permitting long term storage under refrigerated or ambient temperatures (25
◦
C). Traditional freeze 
drying is a slow process since the lyophilization is carried out at temperatures below the glass 
transition temperature of the maximally freeze-concentrated bacteriophage -excipient solution (Tg') 
and below the collapse temperature (Tc) of the sample thereby yielding a porous material with 
microstructure that is conducive for drying. Freeze dried material typically results in a cake that needs 
further processing e.g. milling to achieve fine particles suitable for loading in dry powder inhalers (DPI) 
[112].  
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A brief summary of the main issues surrounding the freeze drying of phage is now given. Papers on 
phage and virus freeze drying have mainly focused on evaluation of formulations in order to stabilize 
phage for storage [105,109,113–115]. A number of papers have shown that addition of amino acids 
(e.g. sodium glutamate [113]), peptides (e.g. peptone [108]) and proteins (casein and lactoferrin [116]) 
to the formulation improves phage viability upon freeze drying and following rehydration (Table 2). 
Literature suggests that disaccharides e.g. lactose [116], sucrose [105,114,115,117] and trehalose 
[77,104,105,114,118] improve phage survival during freezing as well as subsequent lyophilization. 
Osmotic damage is an important factor that reduces phage surviving the freeze drying process [108]. 
This includes hydration stresses which may be ameliorated through addition of sugars to the hydration 
medium [119], something often overlooked in recent studies that use simple buffer or saline for 
rehydrating freeze dried samples [105,114,120]. A number of papers have shown that the 
concentration of sucrose in the formulation affects phage viability during freeze drying and 
subsequent rehydration [105,114], although different phages would appear to prefer either high or low 
concentrations. Rapid rates of freezing at relatively low temperatures (<-20
◦
C) have been found to 
result in better phage survival compared with slow freezing. This has been attributed to having less 
time for osmotic damage to occur [108]. 
 
A detailed listing of literature studies is provided in Table 2 and more detailed commentaries on some 
selected papers are now given as follows. 
 
Engel et al. [113] investigated the storage stability of Mycobacteriophages using freeze drying. The 
effect of various cryoprotectants and lyoprotectants at varying phage titre (10
4
, 10
5
 and 10
9
 PFU/ml, 
for phage BK1) was investigated including sodium glutamate (with and without gelatine), gelatine, 
peptone (with and without sorbitol), dextran (with glucose), calf serum and skim milk. 53 different 
mycobacteriophage were finally tested using sodium glutamate (5wt% with 0.5wt% gelatine). Storage 
of freeze dried phage at room temperature in the dark for as long as 2.5 years resulted in only a 
modest change in phage viability. 
 
Puapermpoonsiri et al. [117] carried out a qualitative study evaluating the effect of sucrose, PEG and 
gelatine during freeze drying on short term viability of S. aureus and P. aeruginosa bacteriophage 
over a 30 day period. Primary drying (freezing and sublimation of frozen water at -30
◦
C for 1000 min) 
was followed by a secondary drying cycle (at an elevated temperature of 25
◦
C for 6h) to desorb 
adsorbed water. The residual moisture content (4 - 6wt%) of the freeze dried powder was found to 
correlate with better phage viability; but due to the qualitative nature of this work, it is difficult to 
accurately assess the magnitude of this effect, which needs further exploration. Gelatine was found to 
play no role in maintaining phage viability following lyophilization. Control of the residual moisture 
content in the lyophilized material was found to be important in order to balance chemical (reactivity of 
amino acids) and physical stability (e.g. unfolding of tail proteins) of bacteriophage resulting in loss of 
lytic activity. High concentrations of sucrose and PEG were needed to prevent collapse of freeze dried 
cakes due to secondary drying at 25
◦
C. High concentrations of additives (e.g. sucrose) lead to a 
decrease in phage titre with better results at lower sucrose concentrations. After 30 days of storage at 
4
◦
C viable phage were still present. Dini and Urraza [105] investigated the effect of buffer systems 
(PBS and SM), buffers with/without skimmed milk and addition of disaccharides (sucrose or trehalose) 
on a Podovirus coliphage stability during freeze drying (at -80
◦
C for 24h) and storage. The coliphage 
freeze dried in SM buffer gave the highest titre compared with skimmed milk and PBS respectively. 
Addition of trehalose or sucrose to PBS did not improve phage titre outcomes. This may have been 
due to hydration stresses due to osmotic shock rather than the freeze drying process. Freeze dried 
samples were rehydrated using a simple buffer rather than a buffer with added sucrose to prevent 
osmotic shock. Addition of sucrose to PBS did stabilise the phage titre upon storage for 120 days (at 
4
◦
C) with phage freeze dried in PBS alone showing a progressive decrease in phage titre over 120 
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days of storage (~2.5 log loss compared with the initial lyophilized product). Addition of sucrose at low 
concentrations (0.1M) in SM buffer was found to result in a high phage titre post freeze drying (only a 
~0.5 log drop in titre attributed to the drying step rather than freezing step) with the titre remaining 
stable for up to 120 days upon storage. Increasing the sucrose concentration in SM buffer to 0.3M or 
0.5M resulted in a ~0.5 log lower titre compared with the 0.1M sucrose sample. Sucrose containing 
powders had a higher residual moisture content, compared with samples dried using PBS or skimmed 
milk. Only a small portion of the overall loss of phage titre (~ 0.3 log) was attributed to the freezing 
step (for the 0.5M sucrose-SM buffer sample) with lyophilization accounting for the majority of the 
~1.5 log phage titre loss. Whether this could be attributed to the rehydration step needs further 
exploration. 
 
One of the only papers to look at rehydration was Cox et al. [119] who looked at loss of phage viability 
arising from detachment of tails from capsid heads due to rapid rehydration following freeze drying. 
Slow rehydration of freeze dried phage by exposure to a controlled humidity environment (100% RH 
at ambient temperature) for 60 min followed by rehydration using broth or sucrose containing broth 
resulted in significantly higher phage titre. The effect of hydration is one area that definitely needs 
further exploration. 
 
Merabishvili et al. [114] investigated the stability of a S. aureus myovirus phage ISP after freeze 
drying. Different formulations containing two different concentrations of phage titres (10
8
 and 10
9
 
PFU/ml) were prepared with different excipients (each excipient at either 0.1M or 0.5M concentration: 
sucrose, trehalose, mannitol, glycine, and polyvinylpyrrolidone (PVP) and PEG 6000 at 1% and 5%). 
Primary drying was carried out at -30
◦
C whereas for secondary drying, the temperature was gradually 
increased to 25
◦
C over a period of ~10h followed by isothermal drying. Some of the excipients (PVP, 
mannitol and PEG 6000) proved to be unsuccessful. PVP was found to inactivate the phage even 
before freezing. Complete inactivation of phage ISP after lyophilization was observed using glycine as 
excipient (glycine crystallizes during freezing). Complete loss of phage ISP activity using the sugar 
alcohol mannitol at 0.1M was observed with a 4 log titre reduction using 0.5M concentration. The 
phage titre thereafter remained stable over a 27 month period with a 2 log reduction after 37 months 
of storage. Phage ISP titre in PEG 6000 showed a 1.8 log (1% PEG) and 5 log (5% PEG) reduction 
following lyophilization. After 37 months of storage, further loss of titre was 3 log (1% PEG) and 1.7 
log (5% PEG). High concentrations (0.5M) of trehalose and sucrose were found to be the most 
effective stabilizers for phage ISP. A 1 log loss in phage titre was observed immediately after 
lyophilization with a further 1 log loss following 37 months of storage. Different concentrations of 
trehalose and sucrose (0.3M, 0.5M, 0.8M and 1.0M) were studied further. Phage ISP freeze dried 
from 0.8M and 1.0M sugar solutions showed the smallest titre reduction immediately after drying (~0.5 
log). Over the next 27 months of storage phage ISP titre remained stable (variability within ~1 log, 
measured at time period 3, 7, 12 and 27 months). Phage ISP stability was also recorded for phage 
stored in LB broth (1 log reduction) and 0.9% NaCl (~ 2 log reduction) over the same period (after 37 
months) stored at 4◦C. Malenovska [115] also reported good results with sucrose in combination with 
gelatine during lyophilization of structurally different animal viruses. It is noteworthy that a 
commercially available freeze dried phage cocktail preparation contains sucrose and gelatine [121]. 
 
Golshahi et al. [116] determined the feasibility of preparing stable freeze dried formulations of B. 
cepacia and P. aeruginosa phage for respiratory delivery. A 2 log reduction in phage titre was 
achieved following freeze drying in a formulation of lactose/lactoferrin (60:40 w/w). Freeze dried 
phage titre remained stable over a 3 month storage period at 4
◦
C and 22
◦
C. Addition of lactoferrin 
resulted in powder that did not require milling to make it respirable (size < 5µm) with ~30 wt% of 
powder available in the free particle fraction (FPF) upon aerosolization. 
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Freeze drying of encapsulated phage  
A number of papers have looked at freeze drying phage incorporated in polymer matrices 
[77,100,118,121,122]. Puapermpoonsiri et al. [100] lyophilized microencapsulated S. aureus and P. 
aeruginosa phage (dispersed in a salt buffer with gelatine) in PLGA (Poly(lactic-co-glycolic acid)). The 
microspheres were frozen in liquid nitrogen followed by lyophilization. All phage viability was lost after 
7 days of storage regardless of storage temperature. Loss of phage viability was attributed to the use 
of an organic solvent in the emulsification process (discussed later). Alfadhel et al. [123] used freeze 
drying as part of the encapsulation process. S. aureus containing nasal inserts were prepared by 
freeze drying (freezing at -30
◦
C and drying at 10
◦
C) phage formulations containing hydroxypropyl 
methylcellulose (HPMC) as the encapsulating polymer. Freeze drying of phages formulated in the 
polymer solution resulted in ~1 log drop in titre immediately after lyophilization and between 3 to 4 log 
reduction over a year of storage at 4
◦
C. Addition of mannitol or increasing the HPMC concentration 
was not found to improve phage stability during storage.  
 
Dai et al. [118] undertook encapsulation of E. coli phage in water soluble polyvinylpyrrolidone (PVP) 
nanofibers prepared using electrospinning. Phage containing PVP solutions (with and without 
trehalose in SM buffer) were frozen in liquid nitrogen and then freeze dried (drying conditions not 
given). Immediately after drying the PVP and PVP-trehalose solutions showed no significant drop in 
phage titre. However, after 8 weeks of storage at room temperature (humidity < 40%) the PVP sample 
showed a 3 log drop in titre whereas the PVP-trehalose sample showed no significant titre drop. 
Korehei and Kadla [106] encapsulated E. coli phage using emulsion electrospinning and co-axial 
electrospinning. In emulsion electrospinning, the phages were pre-encapsulated in alginate 
nanoparticles which were suspended in polyethylene oxide (PEO)/chloroform solution for 
electrospinning. In co-axial electrospinning the aqueous phage suspension remained in the core of 
the fibre whereas the shell was made from polyethylene oxide (PEO). The phage containing fibres 
were freeze dried (details not given). Fibers prepared using co-axial electrospinning were stored at 
20 C, 4
◦
C and -20
◦
C for up to 4 weeks. High phage titre was observed immediately after freeze drying 
of fibres prepared using emulsion (10
6
 PFU/ml) and co-axial (10
8
 PFU/ml) electrospinning. Over 4 
weeks of storage the co-axial fibers showed no loss of phage titre when stored at -20
◦
C and 4
◦
C 
whereas a significant drop in tire (> 6 log reduction) was observed for the samples stored at 20
◦
C. 
 
Recently Colom et al. [77] showed promising freeze drying results for trehalose containing liposomes 
with encapsulated S. enterica phage. Lyophilization resulted in a modest drop (less than 1 log) in 
phage titre for the liposome encapsulated phages. Trehalose containing liposomes showed no loss of 
phage titre when stored at 4
◦
C in 10mM MgSO4 buffer (pH 6.1) for a period of 3 months. 
 
Spray Freeze Drying 
Spray freeze drying may offer the possibility of a single step process to produce bacteriophage loaded 
porous powders with controlled particle-size distribution without subjecting the phage to high thermal 
stresses encountered during conventional spray drying (discussed below). 
 
Leung et al. [104] recently spray freeze dried (using an ultrasonic nozzle to atomize the solution) a P. 
aeruginosa podovirus (PEV2) by spraying the phage solution (formulations containing different 
concentrations of trehalose, leucine and mannitol in combination) directly into a dewar of liquid 
nitrogen; the frozen droplets were subsequently lyophilized (primary drying at -30
◦
C for 24h and 
secondary drying at 25
◦
C for 48h) in a conventional freeze dryer. The ultrasonic nozzle employed high 
frequency vibration (48 kHz) to produce fine droplets; a significant 2 log reduction in phage titre was 
noted just due to the ultrasonic spraying process itself (without freeze drying). The sprayed droplets 
froze immediately upon immersion in liquid nitrogen. Subsequent lyophilization resulted in highly 
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porous dry powder (mean geometric particle diameter ~30µm corresponding to the droplet size 
generated by the ultrasonic nozzle). Particles with high trehalose content (60%) were found to be 
highly hygroscopic and collapsed during storage whilst particles with lower trehalose content (40%) 
retained their porous structure (examined using SEM). The higher trehalose containing particles 
adsorbed more water at lower relative humidity values. Leung et al. [104] suggested handling and 
storage of powders below 20% RH to avoid moisture related recrystallization of excipients damaging 
encapsulated phage. The loss in phage titre post atomization due to spray freeze drying was 
negligible; this suggested that phage activity was preserved by the excipients during the freeze drying 
step as well as the rehydration step. The high phage titre in the spray freeze dried powders was 
attributed to rapid freezing of the droplets in liquid nitrogen resulting in good distribution of the phage 
within the frozen particles. Spray freeze dried powder with the higher trehalose content also had the 
higher phage titre. The aerosol performance (using a commercial DPI device, an Osmohaler
TM
) of the 
freeze dried powders showed a reasonable fine particle fraction (size < 5 µm having 44% phage dose 
~ 10
4
 - 10
5
 PFU dose delivered) with high total recovery of aerosolized viable phage dose (88% - 
97%). 
 
Spray Drying of Bacteriophage for Storage and Encapsulation 
Spray drying processes atomise a liquid containing dissolved solids, converting it into a fine mist 
which is contacted with a hot dry gas (typically hot dry air) inside a drying chamber. Due to the high 
surface area to volume ratio of the very small atomised droplets, the solvent rapidly evaporates with 
each droplet forming a particle comprising the non-volatile components (bacteriophage and 
excipients) along with a small amount of residual moisture. The particles are separated from the 
airstream exiting the dryer, and cyclones or bag filters are typically used for this. Spray drying is a 
scalable industrial process technology and is widely used to produce fine powders for pharmaceutical 
applications including pulmonary delivery via dry powder inhalers (DPI) [124]. Dry powders are 
favoured for respiratory drug delivery because they show relatively long storage stability without 
requiring refrigeration [125,126] and DPI are simple to use and do not require regular cleaning and 
disinfection [127].  
 
Phages have been shown not to be able to withstand high shear stress for too long. The nebulisation 
process has been shown to result in loss of phage titre [104,128]. Phages are also sensitive to 
thermal stresses and have been shown to partially lose activity at temperatures higher than 60˚C 
[108,129]. Low spray drying temperatures (~40 ˚C outlet air temperature) have been shown to result 
in higher phage titre [120] with high loss of phage titre observed at higher temperatures 
[104,128,130,131]. Literature on spray drying of phage suspensions typically includes excipients in 
the formulation to protect the phage from desiccation and thermal stress (Table 2). Upon spray drying, 
sugar excipients form amorphous structures with high glass transition temperatures (Tg), e.g. in their 
anhydrous amorphous form Tg of trehalose is 115 ˚C and Tg for lactose is 108 ˚C. Below the glass 
transition temperature, vitrification due to the excipient stabilises the encapsulated bioactive agent 
and permits storage over long periods at ambient or lower temperatures. Adsorption of moisture 
results in lowering of the Tg and compounds that are hygroscopic e.g. lactose require handling under 
controlled atmospheric conditions (low relative humidity)[131]. Refrigerated storage of spray dried 
powders at relative humidity exceeding 20% has been shown to result in loss of phage titre [120,132] 
whereas samples stored at low humidity were stable. Trehalose is the most frequently reported 
excipient used in the spray drying of phage and it has been shown to result in spray dried powders 
with high phage titre and good storage stability [104,120,131,132]. Trehalose has low toxicity and has 
been shown to protect biological material including proteins, probiotics and vaccines, against 
desiccation and thermal stress. Crowe et al. [133] suggested that the efficacy of trehalose as an 
excipient in drying is partly due to its high glass transition temperature at all water contents but also 
because trehalose binds residual water left over from the drying process to form a dihydrate which 
might otherwise participate in lowering the glass transition temperature to below ambient [132]. Other 
excipients that have been used to improve the dispersibility of spray dried phage containing powders 
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include dextrans [128], lactose (common excipient used for DPI powders; [112,128]), glucose, 
sucrose, mannitol [104] and, leucine [104,131] (Table 2). Reducing sugars such as lactose may be 
unsuitable excipients for bacteriophage [128]. Alternatives such as mannitol have been suggested in 
the literature [134]. Phage spray drying studies using mannitol have reported improved particle 
dispersion characteristics however, phage viability results have been mixed [104,120]. Addition of 
proteins e.g. casein in combination with trehalose have shown good results [131]. Refrigerated 
storage of spray dried powders was reported to yield higher titres of phage during long term storage 
compared with storage under ambient conditions [120]. Different phage strains formulated and spray 
dried under identical conditions showed significant differences in the resulting phage titre suggesting 
the need for individually formulating each phage to be used in a phage cocktail [128,132]. A number 
of studies have reported spray dried phage powders to have a suitable mass median aerosolized 
diameter for pulmonary delivery of phage to treat respiratory infections [104,131,132,135]. 
 
Stanford et al. [75] took a cocktail of 5 E. coli phage (as lysates) which were added to an aqueous pH 
responsive methacrylate polymer (Eudragit S100) containing an unspecified stabilizer, then spray 
dried (co-current spray dryer fitted with a rotary atomizer) into a powder (with 4% moisture content). 
No drying conditions were reported in the paper. The resulting encapsulated phages (described as 
Ephage) were stored at 20
◦
C. Spray drying of the aqueous phage-polymer solution resulted in a 1 log 
reduction in phage titre post drying. Encapsulated phages were shown to survive 20min exposure to 
an aqueous solution at pH3. Storage at 20
◦
C for one year resulted in a decline in phage titre of 
between 1 log and 3 log depending on the phage. Walbeck et al. [130] in a recent patent (assigned to 
Omnilytics, USA) reported a 7 log loss in phage viability post spray drying using E. coli O157:H7 
specific phage (the phage suspensions were unprocessed crude lysates including phage , lysed 
bacteria and fermentation media, no excipients were added, a rotary atomiser was used to generate 
the spray). The loss in phage viability may be attributed to the high air inlet temperature (range 200-
220
◦
C) used which resulted in the dry phage powders being exposed to high air outlet temperatures 
(90-130
◦
C). 
 
Vandenheuvel et al. [135] spray dried S. aureus and P. aeruginosa phages using lactose, trehalose 
and dextran as excipients. Dextran was used not only for its effect as an excipient in the spray drying 
process; in the treatment of respiratory infections it may prevent P. aeruginosa from attaching to lung 
epithelial cells and may increase CF sputum clearance. The effect of atomisation air flow rate and 
drying air inlet temperatures were investigated (using inlet air temperatures of either 85
◦
C or 100
◦
C). 
At a relatively low inlet air temperature of 85
◦
C, the P. aeruginosa podovirus was found to be more 
resistant to spray drying stresses in comparison with a S. aureus myovirus. Lactose and dextran were 
found to be unsuitable excipients, whereas phage viability results with trehalose (4% wt) were more 
promising with less than 0.5 log reduction for the podovirus and a 2 log reduction for the myovirus. 
The effect of air inlet temperature was investigated further using trehalose only. The viability of the 
myovirus was found to be strongly affected by the higher air temperature. At an air inlet temperature 
of 100
◦
C a ~5 log reduction in phage titre was observed in comparison with a ~3 log reduction at 85
◦
C 
using the same air inlet flow rate. The mean particle size (D50) was between 2-6µm. Increasing 
atomisation air flow (which reduced particle size and would have increased atomisation stresses had 
a mildly adverse effect on phage tire). This paper showed that two different types of bacteriophage (a 
myovirus and podovirus) processed under the same conditions show significant differences in stability 
to spray drying stresses and result in significantly different loss of titres. 
 
The same group then assessed the storage stability (over 12 months) of the spray dried S. aureus 
(myovirus) and P. aeruginosa (podovirus) phage using trehalose as excipients [132]. They principally 
investigated the effect of relative humidity (RH 0% and RH 54%) and temperature (0˚C and 25˚C). 
Within 3 months of storage, the S. aureus myovirus titre fell by 2 log (4˚C, 0% RH) and 4 log (4˚C, 
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54% RH) respectively but then stabilised thereafter. At 25˚C almost complete loss of phage viability 
was observed (7 log) for both 0% RH and 54% RH samples after 4 months of storage with a 2 log loss 
observed after the first month. The podovirus was more stable with less than 1 log reduction over the 
12 months for the 4
◦
C sample irrespective of the RH, and between 1 log and 2 log reduction at 25˚C. 
Powder X-ray diffraction analysis (phage free powders dried under identical conditions to the phage 
containing powders) showed that spray dried trehalose powder was non-crystalline. Differential 
scanning calorimetry data showed that the spray dried trehalose had a Tg between 116˚C and 117˚C 
i.e. the trehalose was in an amorphous state suitable for phage vitrification. After 8 months of storage 
at 54% RH, the presence of an endothermic peak between 86 and 91˚C on DSC scans indicated the 
presence of stable trehalose dihydrate crystals. Spray dried trehalose powder samples stored at 0% 
RH did not show changes in DSC endotherms or XRD spectra. Trehalose is known to protect 
bioactive agents from thermal and dehydration stresses through structural and conformational 
stabilization of proteins by direct hydrogen bonding and the process of vitrification. Over time, at 25˚C, 
phage titre dropped even where no crystallisation of the amorphous trehalose was observed.  
 
Leung et al. [104] spray dried a P. aeruginosa phage (podoviridae) designated PEV2 focusing on 
making phage containing powder for pulmonary delivery. The lytic podovirus (supplied by AmpliPhi 
Biosciences, Australia) was used at a titre of 10
7
 PFU/ml suspended in dilute (2 wt% solids) aqueous 
mixtures of trehalose, mannitol and leucine (respective ratios either 60:20:20 or 40:40:20). The 
formulations were designed for use in dry powder inhalers (DPI), as leucine helps improve the 
dispersibility of the powders by reducing cohesive interactions between particles. Mixing phage with 
excipients in solution resulted in a ~0.5 log titre reduction, which was attributed to changes in ionic 
strength when the phage buffer was diluted in excipient solution. Leung et al. [104] used a two fluid 
nozzle for liquid atomisation which itself resulted in a ~ 1 log loss in phage viability. The air inlet 
temperature was 60˚C which resulted in low outlet temperatures of 40-45˚C. The low outlet 
temperature was chosen to minimize thermal stress for the phage. However, titres were lower (due to 
the drying process) than recorded for spray freeze drying process reported using the same phage and 
excipients in the same paper. Spray dried powders were collected inside a relative humidity controlled 
chamber (RH < 20%) and stored at 4˚C. Spray drying resulted in a further ~1.5 log drop in phage titre. 
Leung et al. [120] further investigated the effect of humidity (0%, 22% and 60% RH) on long term 
storage (over 12 months) of spray dried Pseudomonas aeruginosa phage (at 4˚C) dry powders 
containing different amounts of trehalose (40%, 60% and 80%). Storage in a low humidity 
environment (0% and 22%) was found to result in no loss of phage titre. High humidity (60% RH) 
resulted in complete loss of viable phage after 3 months. 
 
Matinkhoo et al. [131] spray dried myoviridae bacteriophage for P. aeruginosa (phiKZ and D3) and for 
B. cepacia (KS4-M and KS14) using trehalose, leucine and casein (a mixture of four similar 
phosphoproteins with MW between 19 kDa and 24 kDa) as excipients. Similar to Leung et al. [120], 
leucine was added to improve the dispersibility of the powder. Surfactants were added to some 
formulations to aid in the dispersion of the bacteriophage in the feed solution [136]. A vibrating mesh 
atomizer was used resulting in atomized droplet diameters around 7µm. Mild spray drying conditions 
were used to provide a low outlet temperature of between 40˚C - 45˚C (air inlet temperature of 75˚C) 
and an outlet relative humidity of less than 7% RH. The spray dryer was housed in a controlled 
humidity chamber with glove ports to allow collection of and storage of powder without exposure to 
moisture. In vitro evaluation of the deposition of the phage loaded spray dried powders was carried 
out using an experimental idealised throat and lung system (Alberta Idealized Throat attached to an 
Anderson cascade impactor) using a commercially available DPI. Four formulations were tested: (i) 
Leucine (77 wt%):Trehalose (19 wt%) (LT); (ii) Leucine (76 wt%):Trehalose (19 wt%):Tyloxapol (2 
wt%) (LTX); (iii) Leucine (76 wt%):Trehalose (19 wt%):Pluronic (2 wt%) (LTP); (iv) Leucine (76 
wt%):Trehalose (19 wt%):Casein (2 wt%) (LTC). All powders had a well dispersed appearance. Small 
batches of material were produced for each formulation; the manufacturing yield of the surfactant 
containing formulations was significantly higher (~ 80 wt%) compared with LT and LTC (~ 60 wt%). 
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Between 20-30 wt% of aerosolized dose (LTX, LTP and LTC) did not reach the lung and was 
entrained in the mouth-throat fraction. In all cases the total lung fraction exceeded 50 wt%. All 
Myoviridae spray dried phages showed a titre loss of less than 1 log. The formulation containing 
trehalose, leucine and the milk protein casein was found to be the best formulation. All the spray dried 
powder formulations prepared by Matinkhoo et al. (2011) delivered more than 50 wt% of dose in the 
correct (< 5 µm size range using the DPI). The LTC formulation was found to most consistently deliver 
single phage doses and cocktails of phage. 
 
A number of in vitro studies have evaluated the use of nebulisers for aerosolization of liquid phage 
formulations for pulmonary delivery. Sahota et al. [137] carried out an in vitro study delivering an 
aerosol containing two different Pseudomonas aeruginosa bacteriophage PELP20 and PELI40 
(isolated from the commercially available Pyophage and Intestiphage preparations from the Eliava 
Institute, Tbilisi, Georgia). A commercial nebuliser was evaluated to deliver the aerosolized phage 
dose into a cascade impactor (phage in the droplet size range less than 5 µm were deemed suitable 
for respiratory delivery); 12% of the nominal dose was aerosolized with less than 0.8% of dose found 
to be in the correct size range for delivery to the lung. Golshahi et al. [138] undertook a study where 
they employed two commercial nebulizers (a jet nebulizer (Pari LC star) and a vibrating mesh 
nebulizer (Pari eFlow)) and estimated that around 50% of nebulized Burkholderia cepacia phage dose 
was in the droplet range (measured using Phase Doppler Anemometry) that would result in deposition 
(estimated using mathematical modelling) in either the tracheobronchial or alveolar region of the lung. 
 
Drying on filter paper 
A couple of early studies looked at stabilising phage by drying phage suspensions by filtering onto 
filter paper and then drying the filter paper [107,139]. Prouty [139] investigated the long term storage 
of bacteriophage of lactic acid streptococci by saturating filter paper with whey filtrate (pH 4.5 - 4.7) 
containing high concentration of phage. Phage titre was not reported however, phages were found to 
remain viable for up to 78 months stored at ambient temperature. Further work is needed to look at 
stabilising phage in porous substrates. 
 
Key points regarding drying of bacteriophage  
Phage drying and encapsulation can be performed using spray drying, freeze drying and spray freeze 
drying techniques. Freeze drying appears to be more successful that spray drying at maintaining high 
titre values, although the ability of spray drying (or spray freeze drying) provides very small particles 
thereby allowing them to be used in DPI for pulmonary delivery, without the need for further milling. 
The best conditions for the spray drying of phage have tended to be with low outlet air temperatures 
(40-60 ˚C) which are much lower than typically used in the spray drying of biological materials (70-100 
˚C). Some of the viability loss in spray drying may be due to the atomisation process. Survival rates 
during subsequent storage additionally depend on temperature and humidity during storage and are 
important considerations for the long term storage of phage. A review of published work on drying of 
phage clearly indicates that phage survival varies from phage to phage and is highly dependent on 
drying conditions and formulation parameters, which need to be optimised for each phage (although 
formulations involving disaccharides tend to be most successful). This presents a considerable 
challenge for phage therapy since cocktails of phage are typically needed. These need to be 
formulated for storage and the active titre of individual phage may be highly variable if all phage are 
formulated together. 
 
Methods Used for Phage Encapsulation in Micro- and Nanoparticles  
Bacteriophages may be encapsulated in protective micro- and nanoparticles to overcome adverse 
storage and physiological conditions en route to delivering the phage load at the site of infection (e.g. 
lungs, intestinal delivery). Controlled release and sustained release strategies for phage delivery 
applications may be achieved using a diverse array of strategies. These include systems based on 
diffusion controlled release (e.g. solvent diffusion based osmotic pumps), matrix dissolution and 
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erosion-controlled systems, ion exchange swelling based systems. Phage compatible formulation and 
encapsulation processes need to be carefully designed to prevent damage to viral capsid and 
DNA/RNA components and stabilization of the structure of viral capsid and tail proteins to prevent loss 
of phage viability during manufacturing operations. It is important that the carrier encapsulating the 
phage is able to withstand adverse environmental conditions for the duration of exposure and is 
capable of delivering the bacteriophage to the site of infection upon arrival [140,141]. 
 
A number of phage encapsulation studies using synthetic and natural polymers have utilised the 
emulsification route followed by solvent removal (Table 3). The dispersed phase usually comprises of 
the core material and solvent carrying the active agent (bacteriophage) and the polymer and a second 
phase which allows for the breakup of the inner phase into droplets. The emulsion may be water-in-oil 
(W/O) more typical for phage encapsulation [100], but could also be oil-in-water (O/W) [142] and in 
some cases a third phase may also be present. Once the droplets have formed, the solvent carrying 
the core material may be removed, which leaves behind solid particles containing the active agent in 
the core. Different mechanical emulsification techniques may be used to break-up the inner phase into 
droplets, such as high-pressure homogenisation, rotor-stator homogenisation, and ultrasonication. 
When two immiscible liquids are put together, shearing force breaks up the inner phase into small 
droplets. The droplet size uniformity however, is low as the shear applied does not remain uniform 
throughout the container resulting in droplet heterogeneity with some droplets being larger and some 
smaller. More advanced methods to produce uniform droplets based on microfluidic and membrane 
based techniques have thus far not been used for phage encapsulation (these methods are discussed 
at the end of the paper). 
 
Alternatively, phage containing polymer droplets have been produced via the extrusion technique 
[143]. The droplet may form in the air or into another liquid. The dispersed phase containing the 
polymer and phage is extruded through a needle with a specific nozzle diameter determining the size 
of the droplet [144]. Atomization nozzles have also been used to generate smaller droplets [78]. If the 
polymer requires a gelling or crosslinking agent then the droplet may be collected in a bath of the 
gelling agent [143,145,146]. Examples of this method are presented by the work of Ma et al. [143,145] 
and Dini et al. [122] where the extrusion technique was employed to extrude alginate containing 
phage droplets into a bath of calcium chloride which caused ionotropic gelation. The process of 
gelation can occur in a number of ways depending on the properties of the polymer/hydrogel. Other 
gelling triggers apart from ionotropic gelation include, heating, cooling and covalent crosslinking. 
Other techniques that have been used for phage encapsulation in synthetic and natural polymers 
include polymer precipitation [147], photopolymerization [148] and thermal phase inversion [142,149]. 
 
Most papers on phage encapsulation in liposomes have used the thin-film hydration method 
[31,39,77,95,150]. Phage have been encapsulated in nanofibers using electrospinning techniques 
[101,106,118,151–153], in films e.g. for wound healing and food biocontrol of pathogens [154,155] 
and in thin film structures [148]. 
 
Polymers used for phage encapsulation 
Studies on phage encapsulation have used a variety of hydrophilic and hydrophobic polymers 
including agarose [148], alginate [78,122,143–145,149,155–157], chitosan [143,158], pectin [122], 
whey protein [149,154,157,159], gelled milk protein [149], hyaluronic acid methacrylate [148], 
hydroxypropyl methyl cellulose (HPMC) [57,123], poly(N-isopropylacrylamide) [147], Poly(DL-
lactide:glycolide) [100], polyesteramide [121,160], polyvinyl pyrrolidone [101,118], polyethylene oxide/ 
polyvinyl alcohol [106,151–153], cellulose diacetate [153], polymethyl methacrylate [161]. Phage have 
been encapsulated in different morphologies including nanospheres, microspheres, nanofibers, 
microfibers,membranes and thin film structures (Table 3). Triggers for phage release include polymer 
solvation, polymer dissolution and erosion [153], polymer hydrolysis [162], phase inversion induced by 
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temperature [147], and pH triggered dissolution of polymer and enzyme driven polymer degradation 
[148]. 
 
Encapsulation of Bacteriophage in Polymeric Microparticles 
Polymer phage encapsulation literature has focused largely on gastrointestinal infections (Table 3). 
The drivers for encapsulation are the need to protect phage from the harsh stomach environment 
rendering free phage inactive or at any rate resulting in reduction in phage titre. High doses of 
bacteriophage need to be delivered in a controlled manner at the site of infection in order to effectively 
reduce the concentration of infectious bacteria present there. This poses a considerable formulation 
and delivery challenge. Animal studies focusing on gastrointestinal infections (discussed above) have 
shown poor efficacy outcomes due to the challenges associated with in vivo phage therapy. Oral 
administration of bacteriophage for human or animal use requires careful consideration of a number of 
factors including: the acidic pH of the stomach, digestive enzymes (pepsin, proteases, lipases, 
amylase and trypsinogen), bile salts, pancreatic juices, residence time in different intestinal 
compartments (duodenum, jejunum, ileum) and phage permeability into the mucosal lining where the 
infection may reside. Without proper formulation, phage may easily be inactivated due to exposure to 
adverse environmental conditions. Carriers designed to protect the active agents e.g. from the harsh 
gastrointestinal environment may also be used to trigger their release. An important example of this is 
pH dependent release of encapsulated phage [75], exploiting the variation in pH throughout the GI 
tract; carriers may be designed to respond to specific pH which differs from the stomach (pH 1-3) to 
the small intestine (pH 5.5-6.5) and the colon (pH 6.5-7.2) [141]. Gastric emptying rates are another 
important factor and need to be considered in the design of phage encapsulation systems for oral use. 
Previous studies indicate that in humans gastric emptying of small microcapsules (less than 2mm) is 
rapid (~ 0.5-1.5 h) and is not greatly affected by the digestive state of the individual [163]. Gastric 
emptying times and environmental conditions in other animals may be quite different to those in 
humans e.g. gastric emptying times in pigs is longer (~1.4-2.2 h) [164]. A suitable biocompatible 
carrier encapsulating the phage may be required to protect and circumvent natural processes of the 
biological system e.g. the acidity of the stomach environment [75]. Triggered release of the phage at 
the site of infection needs to be engineered into the delivery system. For example, the gastrointestinal 
tract may be modelled as a distinct set of compartments (duodenum, jejunum, ileum etc.) with each 
compartment having different environmental conditions (with different pH and transit times)[165]. 
Release of phage in the infected colon may be the desired outcome. High capsule erosion rates 
triggered by a high pH early in the gastrointestinal tract may result in phage release too early with 
poor phage therapy outcomes. The harsh environment of the digestive system renders many sensitive 
therapeutic agents e.g. proteins and phage inactive when administered without due consideration to 
proper formulation [122,166–168]. Owing to the nature of the infection, fluctuations in physiological 
conditions may also need to be considered and may indeed be put to use to trigger release at the site 
of infection [141]. Consideration of particular infection specific symptoms that might influence the 
delivery of the phage needs to be taken into account. For example, the onset of diarrhoea in humans 
causes the osmotic gradient between the epithelia and colon to decrease resulting in increased fluid 
leakage and shorter transit times [169]. Changes in pH have been observed in the intestine during 
infection which can directly affect the microbial population as well as transit times in the GI-tract [170]. 
 
Pathogens that cause systemic diseases may spread by the faecal/oral route and may cross the 
intestinal epithelial barrier by translocation. The small intestine and the ileum are scattered with 
lymphoid tissue that forms the Peyer’s patch (PP) nodules. The PP nodules are overlaid by the 
follicle-associated epithelium (FEM) displaying Microfold cells (M cells). A large number of pathogens 
infecting the human body take advantage of this route to gain access to the host tissues. Salmonella 
typhimurium [171], E. coli [172] and many other pathogens have been shown to adhere preferentially 
to M cells. Targeting the M cells in the PPs may offer the opportunity to deliver phage accurately at 
the site of infection. Using anti-M-cell monoclonal antibodies as specific ligands, adsorption of phage 
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containing micro- or nanoparticles (e.g. liposomes) into PPs may be used to target the M-cell 
membrane [173]. 
 
The micro/nanoparticles must possess specific physicochemical properties such as size, zeta 
potential and hydrophilicity/hydrophobicity balance contained within a narrow range of values [174]. 
Enhancing phage residence time inside the intestine may exploit the mucoadhesive property of 
certain molecules e.g. alginates [78,175,176]. This approach has not met with universal acceptance 
since the superficial mucus layer in the intestine is cleared at a rate between (50–270) min, potentially 
removing anything bound to it. Nanocarriers coated with polyPEG, hyaluronic acid or decorated with 
vitamin B12 have been shown to have a greater ability to diffuse through the mucus layer [177] 
thereby avoiding mucoadhesion.  
 
There is scope for the development of innovative strategies to deliver phage encapsulated in micro- 
and nanoparticles for different target clinical applications. Chemically modified biopolymers provide 
many opportunities for phage encapsulation including aliphatic polyesters, polyamides, polycarbonate 
and poly(amino acids). Synthetic polymers, like Eudragit® are a family of pH responsive 
polymethacrylate polymers; Eudragit® L100 dissolves at pH 6 and Eudragit® S100 at pH 7. These 
polymers are commercially available (Evonik, Darmstadt, Rohm Pharma Germany) and are widely 
used in the preparation of microspheres or for their coating. Eudragit® has been successfully used for 
the production of microspheres encapsulating drugs for colon delivery [178–182]. Combining 
Eudragit® with other biodegradable polymers (mentioned above) may allow tailored systems for 
phage intestinal delivery. “Smart” stimuli responsive polymers with modifiable properties have been 
studied for various applications with tunable pharmacokinetics [147,148,183].  
 
Particle size, surface charge and presence of ligands on the carrier surface play an important role in 
delivery and have so far not been extensively exploited for targeted phage delivery. A vast choice of 
natural and synthetic polymers is available offering considerable opportunities to tailor the 
encapsulation and subsequent release characteristics of phage for different biomedical applications. 
Many carrier systems have been explored for controlled release of therapeutic agents; these include 
polysaccharide polymers, synthetic polymers, liposomes, and micelles, thereby permitting use of a 
multitude of different strategies for encapsulation and release based on different stimuli. 
 
Polymer based controlled release systems have been engineered for the delivery of therapeutic 
agents for enteric applications including treatment of ulcerative colitis, Crohn’s disease [184], 
colorectal cancer and food poisoning as well as many others [185]. The concentration of bacterial 
species in the upper GI tract is approximately 10
3
-10
4
 CFU/ml, largely composed of gram positive 
facultative anaerobic bacteria. In the colon however, this increases significantly to 10
11
-10
12
 CFU/ml 
[186] and is largely composed of anaerobes such as Bacteriodes, Bifidobacteria, Eubacteria, 
Clostridia, Enterococci and Enterobacteria. To survive in this environment bacteria utilise undigested 
substrates present in the small intestine. Carbohydrates like di- and tri-saccharides and 
polysaccharides are fermented by these organisms [187]. . Encapsulation using natural 
polysaccharides is attractive due to their biodegradability by human enzymes. Microbes produce 
enzymes such as β-glucoronidase, α-arabinosidase, β-xylosidase, β-galactosidase, nitroreductase or 
urea dehydroxylase [188]. These enzymes metabolise polysaccharides which the body is unable to 
process. Naturally occurring polysaccharides are popular because they are low-cost and readily 
available offering a wide variety of structures and properties [189,190]. Other polysaccharides used 
for drug delivery applications include; cellulose derived biopolymers e.g. hydroxypropyl 
methylcellulose, pectin derived biopolymers e.g. polygalacturonic acid, guar gum, carrageenans, 
carob bean gum (galactomannans) and dextrin. Amylose, a derivative of starch has been used to 
develop commercially available drug delivery systems, COLAL® and COLAL-PRED® for colonic 
diseases. These polysaccharides utilise the role of enzymatic action by microflora to release the 
encapsulated agent [191,192]. 
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Alginate and chitosan have been used in a number of studies to encapsulate bacteriophage (Table 3). 
Sodium alginate is an anionic linear polysaccharide composed of alternating blocks of β-(14)-linked 
D-mannuronic acid (M) and α-(14)-linked L-guluronic (G) residues. The encapsulation of phage in 
alginates is achieved using mild processing conditions; alginate gelation is achieved by crosslinking of 
carboxylate anions of guluronic acid and calcium ions. Chitosan is a cationic hydrophilic 
polysaccharide obtained by partial deacetylation of chitin; it has been studied for its muco-penetrative 
and tight-junction penetration properties [193,194]. Penetration of the mucosal anionic surface by 
chitosan is determined by the amino groups [195]. Lameiro et al. [196] showed encapsulation of an 
adenoviral vector; for mucosal delivery of vaccines; encapsulation efficiency over 84% was achieved 
with a chitosan coating. Premature release in aqueous media as a consequence of the swelling 
characteristic of chitosan was observed. Takeuchi et al. [197] showed that chitosan coated sub-
micron liposomes interacted with the gut mucosa and had longer residence times in the GI tract. 
Pectin has been used for the encapsulation of phage [122]. Pectin is a polysaccharide of partial 
methyl ester of α-D-galaturonic acid (poly-Gal) interrupted with (12)-α-L-rhamnose units. Pectin 
forms rigid gels through crosslinking of galacturonic acid with multivalent cations. Pectin incorporated 
in liposome nanocomplexes has been shown to result in increased intestinal mucoadhesion and 
prolonged retention in the intestinal mucosa [198]. 
 
Protection from stomach acid, pepsin and bile salts 
Alginate and chitosan have been widely used to encapsulate a variety of bacteriophage for oral 
delivery applications (Table 3). The porosity of alginate gel micro-beads affects phage susceptibility to 
acid damage (when encapsulated phage have been exposed to SGF) due to diffusion of acid into the 
microparticles [122,143,145]; hydrogel pores tend be in the (5-200) nm range depending on the 
degree of crosslinking [175]. Dini et al. [122] showed that acid exposure of E. coli phage (pH 1.6, 30 
min exposure) encapsulated in pure alginate microparticles resulted in complete loss of viable phage . 
L. lactis phage encapsulated in alginate were rapidly inactivated upon exposure to SGF at pH 2 [149]. 
A number of studies have shown that incorporation of calcium carbonate (antacid) within alginate 
micro-beads helps protect encapsulated phage from acid damage [78,145]. The antacid containing 
encapsulated phage were significantly more stable exposed to SGF acidic conditions in comparison 
with free phage. 
 
Blending alginates with other polymers such as neutral gums (e.g. Guar gum [122]), pectin [122], 
chitosan [122,143,145,158], whey protein [149,157,159] and Eudragit [178] has been used to improve 
the acid stability of alginate microparticles.  
 
A number of studies have indicated that phage encapsulated in alginate-chitosan microparticles 
improves phage stability upon exposure to acid conditions however, the protection was not complete 
[122,143,145]. Ma et al ([143], [145]) showed that Salmonella and S aureus phage are sensitive to the 
acidic pH of stomach and therefore required protection for enteric treatment; this was afforded by 
encapsulating phage in composite microparticles containing chitosan and alginate. Only a ~2.5 log 
decrease in Salmonella phage Felix O1 was shown after 1h exposure to simulated gastric fluid 
(containing pepsin) at pH2.4 compared with release of phage at pH6.8 [143]. Kim et al. [158] reported 
promising results for E. coli (Myoviridae) phage encapsulated in chitosan-alginate beads exposed to 
SGF (containing pepsin, 1h exposure at pH2 and pH2.5). For free phage, complete loss of viable 
phage was noted within 5min of acid exposure at pH2 and after 60min exposure at pH2.5. Additives 
such as maltose (disaccharide) have been added to formulations to improve storage stability of 
alginate encapsulated phage to prevent phage loss during air drying of microparticles. Ma et al. [143] 
exposed Salmonella Felix O1 phage encapsulated in chitosan-alginate micro-beads to simulated bile 
containing (exposure for 1h and 3h). Free phage showed a 1 log (1h exposure) and 2 log (3h 
exposure) reduction in phage titre. Microencapsulation in chitosan-alginate beads resulted in 
complete protection of phage to bile salt inactivation. Dini et al. [122] showed that acid exposure of E. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
33 
 
coli phage (pH1.6, 30min exposure) encapsulated in pectin afforded improved resistance to acid 
exposure and protection from pepsin inactivation. 
 
The concentration of encapsulating agent was found to be an important factor in affording phage 
protection from SGF. Increasing whey protein concentration in alginate-whey protein microparticles 
resulted in better acid protection by reducing permeation rates of acid and digestive enzymes [159]. 
Whey protein amino groups may sequester protons diffusing through the polymer matrix. Tang et al. 
[157] encapsulated Salmonella Felix O1 phage in alginate-whey protein microparticles (different 
alginate: whey protein compositions) with high phage loading 10
10
 PFU/g wet particles. Solutions with 
high polymer concentrations (~> 5 w/v%) were found to have high viscosity and posed difficulties in 
extrusion and lead to a wider distribution of particle sizes [157]. Alginate-whey protein microspheres 
were found to be better at protecting Salmonella Felix O1 phage in SGF compared with alginate 
chitosan microspheres [143] prepared by the same group. Exposure of encapsulated Felix O1 to bile 
acid (1h and 3h duration) did not result in significant change in phage titre [157].  
 
Release kinetics of encapsulated phage  
Most studies with alginate containing phage show slow release of encapsulated phage over a 2h-6h 
period upon exposure to SIF [143,158]. Most systems swell upon exposure to SIF and phage release 
is due to diffusion and encapsulation matrix degradation. Ma et al. [143] showed that S. aureus phage 
K encapsulated in chitosan-alginate micro-beads showed a sustained release rate over a 6h period 
(exposure to SIF pH6.8). Microspheres were seen to swell and disintegrate. Addition of calcium 
carbonate in alginate-chitosan micro-beads slowed down the release rate. This was attributed to 
excess Ca
2+
 ions slowing the alginate hydrogel dissolution [145].  
 
Kim et al. [158] exposed E. coli (Myoviridae) phage encapsulated in chitosan-alginate beads to SIF 
(0.1% bile and 0.4% pancreatin, pH7.5, 37
◦
C, 6h exposure). Sustained release of E. coil phage 
encapsulated in chitosan-alginate beads over a 6h period was noted [158]. Sustained release of 
phage (from beads) was shown to result in a ~3 log reduction in the in vitro concentration of E coli 
157:H7 after 5h (compared with ~4 log reduction by free phage). The starting concentration of 
bacteria was 10
6
 CFU/ml. After 10h of incubation in SIF, both free phage and encapsulated phage 
were unable to arrest bacterial growth (comparison with untreated controls) possibly due to presence 
of phage resistant mutant bacteria. Colom et al. [78] showed the in vitro release kinetics in SIF (40min 
exposure, pH8, 1 mg/ml pancreatin, 10mM bile salts, 42
◦
C) for three Salmonella phage (20 
(podovirus), 78 (podovirus) and 87 (myovirus)) individually encapsulated in alginate microparticles 
containing CaCO3. Almost complete phage release was reported within 40 min of exposure to SIF.  
 
Microparticles with different compositions of alginate-whey protein encapsulating Salmonella Felix O1 
phage were exposed to SIF (pH6.8) for 6h [157]. The microparticles were found to swell and 
eventually disintegrate. Encapsulated Salmonella Felix O1 phage showed sustained release profiles 
which varied depending on the amount of polymer content of the particles. For the same alginate 
content, increasing the whey protein concentration was found to slow the phage release rate. Whey 
protein hydrogels tend to swell readily at pH values above the protein isoelectric point (i.e.p. ~pH5.1) 
[199]. Pancreatin may also degrade whey protein provided it is able to diffuse into the hydrogel 
structure. This may explain increasing erosion rates after an initial period of exposure to SIF. Both 
whey protein and alginate possess negatively charged functional groups which would result in 
electrostatic repulsion and swelling of the gel upon exposure to alkaline SIF. Alginate-whey protein 
encapsulated S. aureus phage K released phage over a 2h period upon exposure to SIF (pH6.8) 
[159]. The microspheres were seen to swell and eventually disintegrate with sustained release of 
phage. Changes in formulation resulted in modest differences in the release profiles. Dried 
microspheres resulted in slower release of phage. Increasing concentrations of either alginate or 
whey protein retarded the release of phage K. L. lactis P008 phage encapsulated in alginate-whey 
protein showed a sustained release rate upon exposure to SIF over a 2h period [149]. Pre-exposure 
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to SGF followed by exposure to SIF resulted in a ~1 log reduction in total phage released. Gelled milk 
protein microspheres were also found to be suitably protective of P008 phage and showed sustained 
release of phage upon exposure to SIF over a 2h period.  
 
Effect of size of beads 
Particle size was found to be an important factor influencing phage protection from SGF for acid 
permeable beads [159]. Alginate-whey protein microparticles having the same composition but 
different mean sizes showed larger particles protected phage better compared with smaller 
microparticles [159]. Larger particles keeping phage further away from the acid environment were 
better at protecting phage from acid damage [157]. However, larger particles are expected to 
experience more mastication [159] in the mouth and longer gastric retention [163]. Samtlebe et al. 
[149] encapsulated L. lactis P008 phage in enzymatically gelled milk protein microcapsules with a 
small mean particle size (~130µm) which was shown to protect phage exposed to SGF at pH2 for up 
to 2h. Colom et al. [78] showed that three Salmonella phage individually encapsulated in alginate 
microparticles (size ~ 150µm) containing CaCO3 were able to protect the phage from exposure to 
SGF although reduction in phage titre was noted for phage ~ 3.1 log reduction 78 and ~ 2.4 log 
reduction 87. No loss of titre was noted for phage 20. 
 
Future studies may want to focus on developing methods to control and tailor the porosity of the 
microcapsule shell to protect encapsulated phage from SGF acidity whilst controlling the phage 
release rate. 
 
Storage stability 
Wet alginate-whey protein microspheres containing encapsulated S. aureus phage K showed no loss 
in phage viability over a six week storage period (stored at 4
◦
C) [144]. Dried microspheres (with added 
maltose) were shown to retain phage viability over a two week storage period (no reduction in phage 
titre when stored at 4
◦
C and 20% reduction in phage titre when stored at 23
◦
C). Colom et al. [78] 
stored Salmonella phage encapsulated in alginate/CaCO3 microparticles at 4
◦
C for six months and 
showed only a slight (~25%) reduction in phage titre. Tang et al. [157] air dried (at 22
◦
C) Salmonella 
Felix O1 phage encapsulated in alginate-whey protein microparticles and found an 8-log reduction in 
phage titre. Addition of maltodextrin to the alginate-whey protein microspheres stabilised the phage 
resulting in a < 0.5 log reduction in titre post air drying (drying time 30h, at 22
◦
C). No significant loss in 
Salmonella Felix O1 phage titre was observed for air dried particles over a 2 week storage period 
(stored at 4
◦
C and 23
◦
C). Phage encapsulated in wet alginate-whey protein microspheres stored at 
4
◦
C for 6 weeks showed no significant loss in phage titre. 
 
Phage encapsulation in synthetic polymers 
Surprisingly few studies are available on phage encapsulation in synthetic polymers. Puapermpoonsiri 
et al. [162] freeze dried lytic Staphylococcus aureus and Pseudomonas aeruginosa phage 
encapsulated in PLGA (Poly(lactic-co-glycolic acid)) microspheres prepared using an W/O/W double 
emulsion technique (using dimethylformamide, DMF as organic solvent). The microsphere size was 
designed to deliver the encapsulated phage via inhalation using a dry powder inhaler (1-5µm). The 
phage encapsulated microparticles had low bulk density and aerodynamic diameter ~ 4µm suitable for 
respiratory delivery. Phage activation was retained post particle formation and sustained phage 
release kinetics was noted upon exposure of particles to PBS buffer over a 6h period. Phage release 
showed an initial burst release (within 30min for microparticles suspended in buffer) followed by a 
longer release over ~ 6h suggesting either inhomogeneous distribution of phage within the 
microparticles or reflecting the dissolution kinetics of the polymer microparticles [100]. The formation 
of phage loaded PLGA microspheres necessitated a solvent evaporation step (accomplished using 
freeze drying). No viable phage were recovered from the particles after 7 days of storage at either 4
◦
C 
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or 20
◦
C. Phage inactivation due to exposure to organic solvent (dichloromethane) posed a problem. 
Matsubara et al. [200] evaluated the kinetics of the loss of viability of a filamentous phage exposed to 
four water miscible organic solvents ethanol, acetonitrile, dimethylsulfoxide and DMF; these solvents 
disrupt protein conformation and enzymatic activity [201].  
 
Stanford et al. [75] used Eudragit ES100 (methyl methacrylate-co-methacrylic acid polymer) for 
Escherichia coli specific phage encapsulation for cattle treatment. They showed high sensitivity of the 
phage to the acid in the gastric environment. However, encapsulated phage showed improved viability 
and in vivo reduction in faecal shedding of E. coli following induced infection (discussed earlier in the 
review). The potential of ES100 for encapsulation of phage is also reported in a patent [202]. A 
number of other published studies have looked at phage encapsulation in polyester amide films for 
wound healing applications [121,160]. Thin biodegradable polymer films impregnated with a mixture of 
lytic bacteriophage (containing a mixture of lytic phage (trade name, Pyophage) against P. 
aeruginosa, E. coli, S. aureus, Streptococcus, and Proteus mirabilis, sold under the trade name 
PhagoBioDerm) was employed Markoishvili et al. [121] to treat skin infections. 
 
Hathaway et al. [147] encapsulated S. aureus phage K in Poly(N-isopropylacrylamide), a thermally 
responsive polymer. Phage were encapsulated in PNIPAM nanospheres (~ 500nm) which undergo a 
fully reversible temperature dependent phase transition at a lower critical solution temperature (LCST) 
which results in a change in the particle size due to polymer shrinkage and expulsion of water from 
the nanospheres along with the phage contained therein. The LCST for PNIPAM can vary between 
32
◦
C to 36
◦
C depending on polymer properties [147]. The PNIPAM encapsulated phage nanoparticles 
were grafted on to non-woven polypropylene films (mimicking a wound dressing film) [147]. Evidence 
of temperature dependent phage release data was somewhat limited in this paper. 
 
Bean et al. [148] encapsulated S. aureus phage K in an agarose slab covered in a thin film of a photo-
cross-linkable hyaluronic acid methacrylate (HAMA) polymer. The HAMA polymer was shown to 
degrade in the presence of hyaluronidase enzyme secreted by S. aureus (a rare example of using a 
virulence factor secreted by the pathogen as a trigger for phage release). 
 
Milo et al. [203] describe the use of a pH responsive coating for urinary catheters which may 
immobilize phage and release these upon onset of infection by Proteus mirabilis. Urinary tract 
infections may result in an increase in pH due to bacterial urease which could be used as a trigger to 
dissolve an upper layer of pH responsive polymer (e.g. methyl methacrylate-co-methacrylic acid; 
Eudragit S100) as part of the construction of the catheter hydrogel coating. 
 
Bacteriophage Encapsulation in Liposomes 
Relatively few published studies have looked at encapsulation of bacteriophage in liposomes (see 
Table 4). In nearly all cases the thin-film hydration method has been used for liposome preparation. 
Briefly, this entails dissolving lipids in an organic solvent (typically chloroform) followed by solvent 
evaporation under vacuum leaving a dry lipid film. Addition of an aqueous phage suspension to the 
dry lipid film results in the stacks of liquid crystalline lipid bilayers becoming fluid and swelling. 
Agitation of the solution results in detachment and closure of the lipid layers thereby forming relatively 
large and heterogeneous multilamellar liposomes. Extrusion of the liposome mixture through porous 
membranes has been be used to form smaller liposomes [77,150]. Nieth et al. [47] employed a novel 
method proposed by Weinberger et al. [204] to prepare phage encapsulated in giant unilamellar 
vesicles (GUV) using gel-assisted formation of GUV by rehydrating lipid layers on polyvinyl alcohol 
gels. This technique afforded a number of advantages over the traditional thin film hydration method. 
Firstly, faster hydration kinetics due to aqueous solvent penetration through lipid film stack was 
achieved due to the difference in chemical potentials between the dry PVA supporting the lipid stacks 
and the liquid phase above [47]. Secondly, better encapsulation phage efficiency was achieved with 
the phage incorporated within the cast PVA gel films instead of the rehydration buffer. Confocal 
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microscopy showed visual evidence that this method allowed good encapsulation of a fluorescently 
labelled E. coli  phage . When the E. coli  phage was provided externally with the swelling buffer, no 
encapsulation was observed suggesting that the lipid stacks themselves were impermeable to the 
phage present in the external solution. The GUV prepared using this technique resulted in large 
vesicles (5 µm – 50 µm). Extrusion of GUV through a 5 µm pore size membrane resulted in reduction 
in vesicle size to less than 5 µm however, E. coli  phage concentration was below the sensitivity of 
the fluorescence microscope. No quantitative phage titres were carried out by breaking the liposomes 
and releasing their phage cargo. Nieth et al. [47] also employed the inverse emulsion liposome 
preparation method of Pautot et al. [205] to encapsulate the fluorescent E. coli  phage . GUV 
prepared using the inverse emulsion method had an average diameter between (10µm – 15µm). 
Nieth et al. [47] also showed significantly greater intracellular uptake of liposome encapsulated 
fluorescent E. coli  phage (compared with free phage ) in a macrophage -like human monocytic cell 
line.  
 
Colom et al. [77] encapsulated S. enterica phage in cationic liposomes (liposome size range ~ 200–
800nm). They suggested that cationic liposome loaded bacteriophage would achieve two objectives: 
(i) to protect the bacteriophage from gastric acids and (ii) act as a promoter for mucoadhesiveness 
owing to their positively charged surfaces thereby prolonging intestinal residence time of phage [77]. 
The Salmonella phages were encapsulated in unilamellar liposomes using the thin film hydration 
method. In vitro studies showed that encapsulated phage were released upon exposure to SIF within 
60min. Exposure to SGF resulted in loss of phage viability with modest protection of S. enterica 
phages afforded by encapsulation in cationic liposomes compared with free phages. The intestinal 
residence time of liposome encapsulated phages in the cecum of newly hatched chickens was 
considerably longer compared with free phage (refer to earlier section on animal studies). This was 
attributed to the small size and mucoadhesive properties of the cationic liposomes. Nieth et al. [47] 
also encountered problems in terms of bacteriophage encapsulation in liposomes. Encapsulation 
efficiency, control over the size, phage titre, were found to be key issues that need addressing in 
future studies. Balcao et al. [206] encapsulated lytic bacteriophage (against Salmonella and E. coli) by 
emulsifying an aqueous phage solution (water phase) in a lipid melt (oil phase) using homogenisation 
technique resulting in nanoparticles in the size range (85–200nm). The size of the nanoparticles 
showed stability over a 3 month storage period at room temperature. Quantitative results on the 
antibacterial activity of encapsulated phage were not provided although lytic activity of encapsulated 
phage was observed following phage release.  
 
Singla et al. [39] evaluated the encapsulation of K. pneumonia phage (belonging to the podoviridae 
family) in liposomes prepared using different phospholipid : cholesterol ratios with additional charge 
inducing agents to prevent liposome aggregation. The liposomes were prepared using the film-
hydration method and ranged in size between 500–1000nm. Phage encapsulation efficiency was 
shown to be higher for the electrostatically stabilised positively charged liposomes (containing 
stearylamine) with higher lipid content. Phage encapsulated liposomes stored at 4
◦
C for 9 weeks were 
stable both in terms of size as well as phage titre. Storage at ambient temperature or 37
◦
C resulted in 
changes in size (increase) as well as loss of phage titre. In vivo toxicity testing and biodistribution of 
phage was carried out in mice. Briefly, ~10
8
 PFU dose was delivered to mice via the intraperitoneal 
route. Rectal temperatures were taken hourly (for the first 5h) and daily (for 4 days post phage 
treatment). No adverse change in temperature or symptoms of lethargy or sickness was noted for the 
liposome/phage treated animals. Phage distribution in lungs, liver, spleen and kidney were quantified. 
Blood titres of phage reached ~10 PFU/ml shortly after injection (within 1
st
 hour) for both free phage 
and liposome encapsulated phage. Liposome encapsulated phage remained in blood and other 
organs for longer periods compared with free phage treated mice. Free phage were cleared from the 
blood and organs 48 h post treatment whereas liposome encapsulated phage were detectable in 
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blood and all organs up until day 3 (albeit at low concentrations ~ 1 PFU/ml) post treatment and 
remained detectable in the spleen up until day 14. 
 
Liposomes are spherical structures delimited by a double layer of bulky amphiphilic lipids which 
encloses an aqueous phase. Charge, size, fluidity of the bilayer, lamellarity and surface 
functionalization are the major parameters that regulate liposomes fate in vivo and in vitro. Size and 
lamellarity vary as a result of the manufacturing process. Fluidity and superficial charge depend on 
the chemical nature of the lipids and their relative ratio. Liposomes are also highly biocompatible and 
they have been widely used in the last fifty years to encapsulate hydrophilic or hydrophobic 
therapeutic agents in their aqueous core or within the bilayer thereby enhancing drug bioavailability 
and stability over time. Encapsulated liposomes are a promising drug delivery system and 
pharmaceutical carrier of choice for numerous applications [207].  
 
From a clinical viewpoint the potential ability of liposome encapsulated phage to enter live cells 
containing intracellular pathogens is of crucial importance e.g. M. tuberculosis or other intracellular 
bacteria e.g. S. aureus or E. coil. The surface of liposomes may be functionalized to achieve various 
goals: (i) attachment of specific ligands for targeted delivery of liposome cargo; (ii) attachment of 
hydrophilic polymers to increase systemic circulation time and slow release of bacteriophage cargo; 
(iii) attachment of various labels to monitor the fate of the bacteriophage loaded liposomes; (iv) 
incorporation of positively charged lipid derivatives or positively charged polymers e.g. to aid mucosal 
adhesion thereby improving residence time in the gastrointestinal tract; (v) protection of bacteriophage 
from physical and chemical stresses; (vi) liposome encapsulated bacteriophage may result in 
modulated immune response to the presence of the bacteriophage in the body.  
 
Liposome size, charge and surface modification e.g. PEGylation 
Previous studies have found that by reducing the size of particles below 1µm (i.e. nm scale) 
enhancement in liposome nanoparticle access to infection sites deep in intestinal mucosa may be 
achieved thereby improving phage therapy efficacy by targeting bacterial refugees residing in these 
difficult to access niches [197,198]. The residence time of nanoparticles has been shown to be longer 
compared to larger microparticles; larger particles are more prone to peristaltic action and rapid transit 
through the colon. Nanoparticles have been shown to interact with epithelial cells and show increased 
retention enabling selective delivery of therapeutic agents into the colitis tissue [208]. Conventional 
formulations have so far not exploited this ability causing deposition in regional areas. Smaller particle 
sizes are able to take advantage of endocytosis for internalisation into the epithelial cells of the colon. 
They attach to specialised epithelial M cells (discussed above) which are responsible for antigen 
transport from the lumen to the immune system. These M cells are also responsible for uptake of 
nanoparticles by transcytosis [209]. Microparticles have been shown to adhere to the inflamed 
mucosal wall whereas nanoparticles are absorbed across the epithelial barrier [210]. 
 
Interactions between charged particles and the mucus may be an appropriate strategy for intestinal 
delivery. Cationic delivery systems adhere to the negatively charged intestinal mucosa thereby 
promoting cellular uptake and subsequent drug release [211]. The mucins which comprise the 
mucosa are also known to be negatively charged. Anionic systems adhere to inflamed tissue via 
electrostatic interactions. The presence of positively charged proteins in the inflamed regions typically 
increases. Some authors suggest that unlike cationic particles which get immobilised on the mucus, 
anionic particles are able to diffuse through the mucus network due to decreased electrostatic 
interactions [170]. Other studies suggest that particles are entrapped within the mucin mesh no matter 
what charge they carry since the mucus displays negatively and positively charged proteins. Hence, if 
a non-adherent approach is needed, the nanoparticle surface could be decorated with specific 
moieties that confer so called ‘stealth’ properties [212]. Incorporating poly(ethylene glycol) (PEG) on 
the surface of nanoparticles has been shown to result in a hydrophilic surface chemistry that allows 
unobstructed diffusion of nanoparticles through the epithelium. An explanation for this is that surface 
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modification prevents strong interaction of nanoparticles with the mucus which typically prevents 
diffusion to the colitis tissue [213]. 
 
Active targeting by surface functionalization of phage containing nanoparticles e.g. liposomes with 
ligands for selective phage accumulation at the site of infection may help increase the local 
concentration of phage delivered thereby increasing their therapeutic efficacy. Monoclonal antibodies 
and peptides specific for target sites have been used to increase specificity and enhance muco-
penetrative properties [214]. It is thought that by incorporating ligands targeting receptors present at 
the site of infection may improve binding and thereby intensify endocytosis. Possible receptors for 
targets in the inflamed colon may include, ICAM-1 which is upregulated during inflammation, mannose 
receptors and macrophage galactose-type lectin (MGL) (expressed by activated macrophage). The 
combined effect of the small particle size of nanoparticles, PEGylation and integration of mannose 
ligands has recently been shown to increase penetration ability for macrophage targeting [208]. 
 
Functionalization of liposomes for specific targeting may have an attractive future for phage delivery 
applications. Some pathogenic microorganisms such as M. tuberculosis and S. enterica (serovar 
Typhimurium) are able to survive specific antimicrobial machinery causing persistent infections. Long-
term residence is achieved by internalization in mononuclear phagocyte system (MPS). It is not fully 
understood how these bacteria inhibit their clearance by the immune system but common 
mechanisms include prevention of the normal maturation of the phagosomal environment or blockage 
of the fusion of the phagosome with endosome and lysosome. What happens afterwards is even less 
clear; bacteria can remain stored for years in an asymptomatic state that can suddenly be triggered 
into a potentially life-threatening active state, especially for people with a weak or compromised 
immune system. Liposomes innately accumulate in MPS due to their interaction with serum proteins 
that accelerates phagocytosis. It makes bacteriophage -encapsulated liposomes an appealing 
approach to treat antimicrobial resistant bacterial infections that spread from within the MPS. The rate 
of clearance depends on the physical/chemical characteristics of the vesicle` surface. It has been 
shown that uptake by MPS for liposomes is enhanced when phosphatidylserine incorporating PEG is 
used. On the other hand, long-circulating liposomes with high PEG value can accumulate at the site of 
infection due to increased permeability. Agrawal et al. [215] have demonstrated that Tuftsin, a tetra-
peptide, used as a homing-device improves liposomes uptake by MPS cells but also stimulates these 
cells to take action against infections. Leishmaniasis, Aspergillus fumigatus and Mycobacterium 
tuberculosis infections have been treated with drug-loaded tuftsin-bearing liposomes and tuftsin-free 
liposomes and in all cases the treatment lead to enhanced effectiveness. 
 
Phage therapy has recently been considered as an alternative to, or a supplement for, antibiotic 
treatment for mycobacterial respiratory infections. However, phage therapy for TB and other 
respiratory infections caused by non-tuberculosis mycobacteria (NTM) is complicated by the 
intracellular nature of the infection. It is generally recognised that phage do not diffuse across 
eukaryotic cell membranes and therefore would be unable to infect the intracellular mycobacteria [48]. 
Using a non-pathogenic mycobacterium, Mycobacterium smegmatis, infected with a 
mycobacteriophage as a ‘Trojan horse’ to deliver phage to the macrophage compartments in which M. 
avium resides, showed promise when tested in vitro with infected macrophage [216]. However, when 
used in a murine model of M. avium infection, this approach was less effective. It was deemed that 
the numbers of infected M. smegmatis cells required, would deliver too large a dose of antigenic 
material to be acceptable [217]. Alternative methods of delivery of phage to intracellular mycobacteria 
have been sought. Looking to the relatively routine use of liposome encapsulation for intracellular 
delivery of small molecule drugs [218], Neith et al. [150] recently suggested encapsulation of phage 
within liposomes may result in uptake of phage and delivery to the required intramacrophage 
compartment to initiate lytic infection of intracellular pathogens. To this end, they demonstrated 
successful encapsulation of mycobacteriophage TM4 in giant unilamellar vesicles. Furthermore, by 
encapsulation of a lambda phage expressing yellow fluorescent protein and fluorescent labelling of 
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macrophage endosomal proteins, they were able to demonstrate intracellular delivery and co-
localisation of the lambda phage and the endosomes; in Mtb infected macrophage , the mycobacterial 
phagosome fuses with early endosomes. This demonstration that liposome-encapsulated phage could 
gain access to the target mycobacteria satisfies a requirement for effective therapeutic use of 
bacteriophage to treat intracellular mycobacterial infections. A previous study using liposome 
encapsulation of frontline antituberculosis antibiotics, rifampicin and isoniazid, showed enhanced 
treatment in a murine infection model of Mtb compared with treatment with antibiotics alone [219]. The 
efficacy of a liposome-encapsulated mycobacteriophage to treat Mtb infection in macrophage or 
animal models remains to be demonstrated. 
 
Encapsulation of bacteriophage in liposomes may be a potential approach to tackle antibiotic resistant 
bacterial infections in wounds. Previous studies have shown that topical applications of buflomedil 
hydrochloride loaded liposomes in mice significantly accelerate wound epithelialization [220] in normal 
and ischemic tissue. Furthermore, by modifying the liposome surface properties (e.g. charge), 
liposomes can be trapped in gauzes [221] reducing the number of applications and consequent costs. 
The surface of liposome vesicles can be modified with hyaluronic acid (HA) in order to confer 
bioadhesive properties [222]. Indeed, HA-anchored liposomes were found to bind to the extracellular 
matrix (ECM) without compromising any of the liposome properties. A marked enhancement of 
liposomal adhesion (in vitro) to a monolayer of human epidermoid carcinoma cells was observed. 
Topical delivery of bacteriophage -loaded liposomes would constitute a phage reservoir localised in 
the area of the wound area releasing phage at a high concentration over an extended period of time.  
 
Phage Encapsulated in Electrospun fibers 
Fabrication of phage encapsulated polymer fibers (diameters ranging from tens of nanometers to 
microns) may readily be achieved using electrospinning, by drawing a charged polymer-in-solvent 
solution onto a grounded electrode while evaporating the solvent. A number of studies have shown 
the feasibility of encapsulating phage in nanofibers using the electrospinning technique (Table 2). A 
number of different polymers have been evaluated for encapsulating phage in fibers including 
cellulose diacetate [153], polyethylene oxide [106,153], polyvinyl alcohol [151,152] and polyvinyl 
pyrrolidone [101,118]. Good phage encapsulation results have been reported using water soluble or 
chloroform soluble polymers [106,118]. Rapid dehydration during electrospinning was shown to 
damage phages. Use of buffer and incorporation of sugars e.g. trehalose was shown to improve 
protection of phage [118]. Protection of phages in core-shell fibers using co-axial electrospinning 
technique was shown to be particularly promising [106,153]. Using immiscible solvents for the core 
(phage contained in an aqueous core) and shell (shell polymer dissolved in an organic water 
immiscible solvent) was found to stabilise the polymer jet resulting in the formation of a stable core-
shell fiber structure [106,153]. In this process, aqueous solvent evaporation from the core is very slow 
thereby overcoming drastic changes in osmotic pressure in the phage containing core. Encapsulation 
of phages in nanoparticles formulated in an emulsion followed by electrospinning of the emulsion was 
another approach that was shown to result in improved phage protection during electrospinning [106]. 
Increasing polymer molecular weight or blending different polymers (e.g. cellulose acetate/PEO) was 
shown to result in changes in the phage release kinetics from electrospun fibers [153]. The main 
reported mechanism of phage release from encapsulated fibers is typically swelling of fibers upon 
exposure to solvent followed by polymer erosion accompanied by phage diffusion and release. 
Encapsulating phage in hydrophilic water soluble polymers results in rapid phage release due to 
polymer dissolution whereas use of hydrophobic polymers or blends may allow tailoring of phage 
release to ensure slower release over a prolonged period.  
 
 The polymer and solvent combination used for fiber production were found to be important factors in 
the formation of nanofibers and retention of phage viability therein. Lee and Belcher (2004) spun 
fibers (diameters 100-200nm) containing E. coli M13 phage which retained infectivity against bacterial 
host when re-suspended in buffer. The phage containing fibers were spun from an aqueous polyvinyl 
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pyrrolidone buffered solution containing phage ; the fibers were captured as a non-woven fibrous mat. 
Concentration of viable phage in the fibres was not reported. Salalha et al. [152] and Kuhn [151] 
encapsulated T4, T7, and  E. coli phage in electrospun nanofibres (diameter 250-400nm) prepared 
from aqueous poly(vinyl alcohol) (PVA) solutions. Nanofiber encapsulated phage were shown to 
retain viability and remained stable for three months stored at -20
◦
C and -55
◦
C and nearly so at 4
◦
C. 
Salalha et al. [152] suggested that this method was a facile way of preserving phage . Immediately 
after electrospinning, a 2 log loss in phage viability was reported (T4 ~ 1%, T7 ~ 2% , and  ~ 1%). 
The losses in phage viability during electrospinning may be attributed to drying stresses due to rapid 
evaporation of solvent and drastic changes in osmotic pressure experienced by phage. Dai et al. [118] 
investigated electrospinning (diameter 100-200nm) of E. coli T7 phage in SM buffer using PVP as 
polymer (15% w/v) and trehalose (5% w/v) as excipient as a means to improve phage stability for long 
term storage. Inclusion of SM buffer had a significant effect on phage viability post electrospinning. 
The phage titre of PVP/SM buffer samples (with and without trehalose) fell by no more than ~1 log 
following electrospinning. Electrospinning phage -PVP solutions in deionised water resulted in a 4 log 
reduction in phage titre. Addition of trehalose to deionised water resulted in some improvement with a 
2 log reduction post electrospinning, showing that trehalose had a protective effect. Dai et al. [118] 
also compared phage stabilisation using electrospinning with freeze drying. Phage encapsulated in 
electrospun fibres (made from SM buffer with trehalose) were found to have similar titre compared 
with freeze dried powder samples. Storage of phage T7 in electrospun fibers for eight weeks (stored 
at 20
◦
C) resulted in a 3 log reduction in phage titres for samples prepared from SM buffer with/without 
trehalose.  
 
Korehei and Kadla [106] evaluated emulsion electrospinning (pre-encapsulating phage in ~ 800nm 
alginate microparticles followed by lyophilization and then re-suspension in a polymer containing 
solvent followed by electrospinning) and coaxial electrospinning (incorporating the phage in a 
protective core in a core-shell fiber structure) processes to encapsulate E. coli T4 phage in 
polyethylene oxide fibers. The process of encapsulating phage in alginate nanoparticles resulted in a 
1 log drop in phage titre. Freeze drying the phage encapsulated in nanospheres did not result in a 
drop in phage titre. Electrospraying the alginate suspension on its own (without polyethylene oxide) 
resulted in a large drop in phage titre from 10
8
 PFU/ml to 10
3
 PFU/ml. Polyethylene oxide (PEO) is 
soluble in both aqueous and organic solvents making it a suitable polymer for electrospinning. 
Polyethylene oxide fibers encapsulating alginate nanoparticles were found to result in fibers with a 
bead-on-string morphology (fiber diameter ~ 1µm). Dissolution of fibers in SM buffer showed a phage 
titre of 10
6
 PFU/ml (a 2 log reduction). Fibers with diameter ~ 2 µm were prepared using a core/shell 
approach with the fiber shell made using PEO in chloroform and the core containing T4 phage in SM 
buffer [106]. Good lytic activity was retained post electrospinning with a high phage titre obtained (10
8
 
PFU/ml) with fibers dissolved in SM buffer. Storage stability of T4 phage in the core-shell fibers after 
freeze drying (freeze drying conditions were not reported in the paper and no details were given on 
whether any excipients were added) was investigated (stored at -20
◦
C, 4
◦
C and 20
◦
C) over a period of 
30 days. No significant loss in phage titre was observed for samples stored at -20
◦
C and 4
◦
C. Storage 
at 20
◦
C resulted in a significant loss (> 6 log reduction) in phage titre. Upon exposure of PEO fibers to 
SM buffer, fibers were seen to swell followed by disintegration (within 10min) resulting in release of 
phage for the alginate-emulsion based fibers and the core-shell fibers. Initial rate of phage release 
was faster from the core-shell fibers (the resulting final titre was also higher) compared with the 
alginate nanoparticle encapsulated fibers. Korehei and Kadla [153] varied the molecular weight (MW) 
of PEO (100kDa – 600kDa) and blended hydrophilic PEO with the hydrophobic polymer cellulose 
diacetate (CDA). E. coli T4 phage encapsulated in fibers produced using different PEO/CDA showed 
slow release of phage depending on the PEO MW and the ratio of PEO/CDA. Higher PEO MW 
(results in increased polymer entanglements) and greater proportion of hydrophobic CDA (slower rate 
of polymer swelling and erosion) resulted in slower release of phage. 
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Immobilisation of phage on surfaces including thin films 
Microbial biofilms on medical devices e.g. urinary and central venous catheters, stents, implants, 
invasive health monitoring devices, are a significant healthcare problem and are responsible for a vast 
majority of medical device associated infections. Bioactive packaging materials are also attractive in 
other areas including food packaging e.g. ready-to-eat meat, ready cut fruits and poultry [155]. 
Antibiofilm formation strategies include oriented immobilization by covalent attachment of 
bacteriophage to polymer surfaces [223] or immobilisation of bacteriophage in stimuli responsive 
surfaces where release is triggered in response to an external stimulus [148]. Although phage 
immobilisation on surfaces may readily be achieved through passive adsorption [224], the process is 
inefficient with loss of phage activity due to poor orientation of phage tails needed to recognise and 
infect target bacteria. Chemical biotinylation of the phage capsid head has been used for oriented 
immobilisation (to retain phage lytic activity by leaving the tail fibers free in order to capture bacteria) 
of a Salmonella enteritidis phage on streptavidin-labelled magnetic beads [225]. Tolba et al. [226] 
used phage display technology to introduce affinity tags on the capsid head to immobilise E.coli 
phage on streptavidin coated magnetic and cellulose beads. Pearson et al. [223] covalently attached 
lytic E.coli and S. aureus phage through reaction of primary amine groups on the capsid head with R-
COOH surface groups (generated using microwave plasma in the presence of maleic anhydride) on 
polyethylene and polytetrafluoroethylene surfaces. Anany et al. [227] and Lone et al. [155] utilised the 
electrostatic interaction between the anionic capsid head of E. coli O157:H7 and Listeria 
monocytogenes phage cocktails and polyvinylamine treated cellulose membranes. Modification of 
cellulose membranes resulted in greater numbers of infective phage oriented correctly. A recent 
patent focuses on controlled covalent attachment of bioactive bacteriophage to a hydrogel coating 
material for regulating biofilm development with examples focusing on biofilm reduction on urinary 
catheters [228]. An earlier patent gave examples of phage immobilisation on nylon sutures for wound 
healing applications [229]. Cooper et al. [230] used carbodiimide oriented covalent attachment of a 
tailed P. aeruginosa bacteriophage to magnetised multiwalled carbon nanotubes. Preliminary results 
showed antimicrobial efficacy of bacteriophage -nanocomposite conjugates against P. aeruginosa. 
Handa et al. [231] employed chemical vapour deposition to make a smooth aminosilane monolayer on 
a glass substrate. Subsequently, monolayers of covalently bound Salmonella specific phage were 
attached to the aminosilane monolayer using well-established sulfo-NHS (N-Hydroxysulfosuccinimide) 
and EDC (1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride) chemistry [231]. Techniques 
for attachment of phage to gold substrates has been investigated to increase their diagnostic utility as 
part of quartz crystal microbalance (QCM), surface plasmon resonance (SPR) transduction based 
diagnostic platforms [232] or direct detection as part of virus electrodes [233]. Recently, Richter et al. 
[234] applied an electrical potential to align E. coli phage T4 and drive them to the electrode surface 
resulting in head down, tail-up orientation resulting in increased sensitivity of phage for bacteria and a 
low detection limit for E coli of 10
3
 CFU/ml. Tawil et al. [235] reported on the synthesis of colloidal 
phage -gold nanoparticle complexes for the detection of a single S. aureus bacterium in a mixture of 
S. aureus and E.coli using Dark Field Microscopy. The potential of phage for biosensing applications 
including low-cost medical diagnostics may require their coupling with novel materials (thin film 
constructs, magnetic, metallic, polymer nanoparticles, quantum dots) [24]. 
 
Future Trends in bacteriophage formulation and encapsulation 
 
Phage encapsulation using novel stimuli responsive materials 
There is significant scope for future research on encapsulation of phage in novel stimuli responsive 
polymers utilising different triggers for phage release including light, temperature, pH, enzymes. A 
wide range of external stimuli may be used to trigger self-assembly of phage containing micro- and 
nano- particle structures (e.g. in micelles, nanogels, capsules, vesicles, core-shell particles, hybrid 
particle-in-particle structures, emulsions and foams) and may induce their reversible or irreversible 
disintegration, aggregation, swelling. Micro- and nanoparticles with surface grafted ligands may be 
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used for targeted delivery of phage cargo released at the site of infection. Stimuli responsive homo-
polymer and mixed-polymer brushes grafted on to microparticles may be used to trigger phage 
release in response to changes in environmental or interfacial conditions. Phage may be 
encapsulated in different architectures e.g. thin film structures as multi-layered films, hybrid films 
combining polymers and nano- or micro- particles.  
 
Phage Encapsulation using Membrane Emulsification 
Advanced techniques may be applied for phage encapsulation to precisely control the size and 
architecture of phage containing micro- and nano- particles. To-date methods used for phage 
encapsulation have not utilised state-of-the art processing techniques that could be applied for the 
encapsulation of phage to achieve controlled dosage forms in uniform micro- and nanoparticles. 
Membrane emulsification (ME) is one such process that allows formation of uniform drops by injecting 
a dispersed phase liquid through a microporous membrane into the continuous phase (Figure 3a). 
Alternatively, a pre-emulsified mixture of the dispersed and continuous phase may be repeatedly 
injected through the membrane (Figure 3b). To encapsulate bacteriophage , the formed drops, 
typically composed of a mixture of the wall forming materials, solvent(s) and phage , could be 
solidified under mild agitation using various solidification reactions or processes, such as free-radical 
polymerisation, polycondensation, ionotropic/thermal gelation, cooling crystallisation, and molecular or 
particle self-assembly triggered by solvent evaporation [236]. The advantages of ME over standard 
emulsification procedures using high-pressure valve homogenisers or rotor-stator devices are in 
higher drop size uniformity and lower energy inputs and applied shear, which can be useful to 
preserve phage integrity. It is well known that bacteriophage are sensitive to mechanical shearing 
[104,128]. In direct ME, the shear rate on the membrane surface is ~10
3
-10
4
 s−1 however, uniform 
drops may be obtained without any shear by spontaneous droplet formation driven by Laplace 
pressure gradients [237]. The shear rate in high-shear mixers and colloid mills is typically ~10
5
 s−1 and 
can exceed 10
7
 s−1 in microfluidizers. The most common membranes used in ME are Shirasu Porous 
Glass (SPG) (Figure 3c) and microsieve metallic membranes [238]. Shear on the membrane surface 
required for drop detachment can be generated in various ways including; (i) using a paddle stirrer 
placed above the membrane surface (Figure 3d) [239]; (ii) rotating membrane [240] and (iii) oscillating 
membrane [241]. In the oscillating ME system, the tubular membrane can oscillate tangentially 
clockwise or counter-clockwise [242] or radially upward and downward (Figure 3e) [241], with 
frequencies ranging from 10 to 90 Hz. 
 
Phage Encapsulation using Microfluidic Emulsification 
Bacteriophage containing microcapsules could be fabricated using microfluidic devices with 
unprecedented uniformity and control over the size, shape and morphology [243,244]. The process 
involves creation of drops in a variety of geometries consisting of micrometre length scale channels 
designed to bring two or more immiscible fluid streams into contact with one another. This is followed 
by conversion of the generated drops into solid particles (using techniques discussed earlier). The 
variation of drop sizes in microfluidic devices is negligible (less than 3%) and encapsulation efficiency 
of bacteriophage can reach 100%. The drop productivity can exceed 10,000 drops per second [245], 
however, the flow rate of the dispersed phase is modest (0.01-10 mL h
-1
 per drop generation unit - 
DGU). The most common planar DGUs are co-flow drop makers in which immiscible fluids meet in 
parallel streams, cross-flow drop makers or microfluidic junctions in which the immiscible fluid streams 
meet at an angle to one another, and flow-focusing drop makers in which there is a geometric 
element, such as a constriction, that causes the streams to accelerate, narrowing the inner fluid 
thread and causing it to break into drops [243].  
 
Microfluidic emulsification allows for precise fabrication of structured multiple emulsions with 
controlled drop morphology. Conventional multiple emulsions are composed of numerous drops of the 
inner phase dispersed within larger drops of the middle phase, which itself is dispersed in an outer 
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phase (Figure 4a). The middle phase must be immiscible with both the inner and outer phase. A 
W1/O/W2 emulsion consists of drops of the inner water phase W1 dispersed within the oil drops, which 
are then dispersed in the outer water phase W2. Bacteriophage typically would be suspended in W1 
phase and the oil phase would contain a suspended or dissolved encapsulating shell material such as 
a polymer. Microfluidic methods can be used to produce multiple emulsion drops consisting of a 
controlled number of inner drops encapsulated within each large drop (Figure 4b) [246]. The number 
and content of individual inner drops can be controlled thereby allowing the loading of bacteriophage 
to be precisely manipulated [246,247]. The distinct inner drops can be used to achieve simultaneous 
encapsulation of two or more types of bacteriophage in separate microenvironments and to control 
the loading for each of them. Thus phage cocktails may be individually formulated to overcome the 
limitations of one formulation having to suit all. 
 
Microfluidic methods can be used to prepare multiple emulsion drops with concentric onion-like shells 
around the core drop (Figure 4c). Droplets with different numbers of shells may be synthesised 
depending of the number of immiscible phases within each drop e.g. double (W1/O/W2 or O1/W/O2), 
triple (W1/O2/W3/O4 or O1/W2/O3/W4), quadruple (W1/O2/W3/O4/W5 or O1/W2/O3/W4/O5), and quintuple 
(W1/O2/W3/O4/W5/O6 or O1/W2/O3/W4/O5/W6) [248]. High-order multiple emulsions may be useful in the 
production of complex capsules for co-encapsulation and simultaneous or sequential release of 
several multi-component actives (Figure 4c) [249]. Multiple shells would allow tailored formulations 
within a single capsule e.g. an outer acid stable shell may protect phage from the stomach acidity, an 
inner burst release shell for bolus delivery of phage with an innermost sustained release shell 
resulting in slow sustained phage release over a significant time period negating the need for 
repeated phage dosing. 
 
Other approaches might include phage encapsulation in Janus particles composed of two 
hemispheres with various physical and chemical properties (Figure 4d). Janus drops typically have 
two distinct regions of roughly equal surface area, however, the term has expanded to include all 
multi-segment droplet structures with regions of different composition co-existing in asymmetric 
geometries [250]. Janus particles may be used to encapsulate bacteriophage in different polymers 
having different in vivo degradation rates to achieve burst release followed by controlled sustained 
release.  
 
Conclusions 
Implementation of phage therapy necessitates the use of phage cocktails to overcome the limited host 
range of an individual phage and the risk of phage resistant bacterial mutants. High doses of phage 
need to be reliably delivered at the site of infection. Repeated frequent dosing of phage may be 
impractical hence, encapsulation of phage in sustained release systems is needed. Bacteriophage 
susceptibility to chemical and physical stresses differs among phage families and also within a family. 
Careful consideration needs to be given to ensure the formulation chemistry and processing 
conditions are suited to phage making-up the cocktail in order to ensure reproducible retention of high 
phage titres and stability during long term storage. Further research is urgently needed in the field of 
phage formulation and encapsulation to adequately support any future phage therapy field. 
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Appendix: Mathematical model of bacteria/phage interaction. 
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Here  
S, R - concentrations of susceptible and resistant bacteria accordingly [CFU ml
-1
],  
P1 - concentration of the phage affecting susceptible bacteria only [PFU ml
-1
], 
P2 - concentration of the phage affecting both susceptible and resistant bacteria [PFU ml
-1
], 
T - latent period [min]; index ‘T’ indicates the value of the variable T minutes in the past,  
g - bacteria growth rate [min
-1
],  
a - (bacteria/phage) adsorption coefficient [ml min
-1
 PFU
-1
],  
n - average number of phages adsorbed by an individual bacterium,  
b - burst size,  
m - probability of bacteria mutation resulting in resistance to phage P1,  
d - phage death/removal coefficient [min
-1
].  
 
For both figures in the paper the following values were used: g = 0.02 min
-1
, n = 1, b = 30, m = 10
-5
, d 
= 0.02 min
-1
. 
For the results shown in Figure 1    a = 10
-10 
ml/min, T=40 min.  
For the results shown in Figure 2    a = 0.5*10
-10 
ml/min, T=60 min. 
 
Also, for any given latency period T a discrete distribution in the range 0.76T – 1.24T was used 
instead of the fixed T. It was T for 48% of infected bacteria, 0.88T for 20%, 1.12T for 20%, 0.76T for 
6% and 1.24T for 6% - as the figure below illustrates for T=30 min.  
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Table 1. Summary of phage therapy animal studies to treat acute local, systemic, gastrointestinal and pulmonary bacterial infections.  
R
e
f.
 
Host organism Animal Infection Delivery 
b - bacteria 
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[66] Ec           ??       Sy       bp 
b 
 
p 
          7 2-8 * ?? ?? ?? ?? ?? ?? ?? 
[69] Ec            ??       Se      bp            6 2-6 ⁂  ?? ??  ??  ?? 
[69] Ec            ??        M       bp          3 6-8 * ?? ?? ??  ??  ?? 
[67]  Ef          ??       Sy          bp         9 8 *  ??  ?? ??   
[68]   Vv         ??       Sy   L     p   b        2-6 4-8 *  ?? ?? ?? ??   
[71]    Sa          ??     Sy          bp         9 9-11 * ?? ??  ?? ??   
[33]    Sa          ??         W       bp        8 6-9 * ??  ?? ?? ??   
[34] 
    Pa       ??           W   
p 
 
  
 
 
 
 
 
p 
b 
bp 
b 
 
 
       
2 8 ⁂ 
 ?? ??   ??  
[29]    Sa        ??       Sy   L     bp   bp        8 7-9(R) * ?? ??   ??   
[31]      Kp      ??       Sy          pΦ  b       4 9, 7(E) *  ?? ?? ??   ?? 
[69]  Ec              ??         G  p      b      10 10 * ?? ?? ??   ??  
[83]  Ec           ??            G        b p     4-8 5-6 ⁂ ?? ?? ??    ?? 
[64]  Ec           ??            G        bp*      9 8-10(R) ⁂  ?? ?? ?? ??   
[73]        Cj      ??           G        bp      5 9-10 */ ⁂ ?? ?? ?? ??   ?? 
[70] 
    Pa       ??            G  
   bp 
 
  bp      
6-10 10 * 
 ?? ?? ??   ?? 
[74]          Se   ??           G        bp      4 8 ⁂  ?? ??     
[75] Ec              ??         G        bΦ      11 10-11 ⁂  ?? ??    ?? 
[57] Ec               ??        G        bΦ*      5 ~5(R) ⁂  ?? ??     
[55]           Cd      ??       G        bp*      4 ~8(R) */⁂  ?? ??   ??  
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[78]          Se   ??           G        bΦ      7 10(R) ⁂  ?? ??     
[77]          Se   ??           G        bΦ      7 10(R) ⁂  ?? ??     
[58]        Vc    ??            G        bp*      5, 8 5-7, 8 */⁂  ?? ??  ?? ?? ?? 
[58]        Vc      ??          G        bp*      8 9 */⁂  ?? ??   ?? ?? 
[59]          Se        ??      G        bΦ      9 ~10(R) ⁂  ?? ??    ?? 
[80]          Se  ??            G        bp      6 ~10(R) ⁂  ??     ?? 
[80]          Se   ??           G        bp      5 ~10(R) ⁂  ?? ??     
[92] Ec            ??            P p      p  p     6-8 ⁂   ??     
[90] Ec            ??            P         p b   4 7-9 ⁂  ?? ?? ??   ?? 
[42]         Bc   ??             P     p p     b b 7-9 7-9 * ?? ?? ?? ??    
[26]     Pa       ??             P            bp 7 7-9 * ?? ?? ?? ?? ??  ?? 
[27]     Pa       ??             P            bp 7 8 ⁂  ?? ??     
[41]     Pa       ??             P            bp 6 6-8 * ?? ?? ??  ??  ?? 
[31]      Kp      ??             P     pΦ       b 4 2-4 * ?? ?? ?? ??   ?? 
[32]      Kp      ??             P     p       b 7-8 9-11 *  ?? ?? ??   ?? 
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Table 2. Summary of studies looking at effects of formulation, drying and storage on phage viability.  
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B
. 
c
e
p
a
c
ia
 
C
. 
u
lc
e
ra
n
s
 
E
. 
c
o
li 
 
M
y
c
o
b
a
c
te
ri
o
p
h
a
g
e
 s
 
P
. 
a
e
ru
g
in
o
s
a
 
S
. 
a
u
re
u
s
  
S
. 
e
n
e
te
ri
c
a
 
V
. 
c
h
o
le
ra
e
 
O
th
e
rs
 
B
ro
th
 /
 l
y
s
a
te
; 
 
B
u
ff
e
r 
S
a
lin
e
 
W
a
te
r 
G
e
la
ti
n
e
 
G
ly
c
e
ro
l 
P
ro
te
in
s
. 
(c
a
s
e
in
, 
w
h
e
y
 e
tc
.)
 
A
m
in
o
 a
c
id
s
 o
r 
p
e
p
ti
d
e
s
 
T
re
h
a
lo
s
e
 
M
a
n
n
it
o
l 
S
u
c
ro
s
e
 
P
o
ly
v
in
y
lp
y
rr
o
lid
o
n
e
 
L
a
c
to
s
e
 
L
e
u
c
in
e
 
O
th
e
rs
 
( ) -encapsulated 
B
e
fo
re
 S
to
ra
g
e
 
Storage conditions 
brown/blue – low/high relative 
humidity 
F
re
e
z
e
 d
ry
in
g
, 
A
ir
 d
ry
in
g
 
D
ry
in
g
 o
n
 f
ilt
e
r 
p
a
p
e
r 
 
S
p
ra
y
 d
ry
in
g
 
S
p
ra
y
 f
re
e
z
e
 d
ry
in
g
 
S
to
re
d
 a
s
 l
iq
u
id
  
S
to
ra
g
e
 d
u
ra
ti
o
n
, 
m
o
n
th
s
  
(L
T
 –
 l
o
n
g
 t
e
rm
) 
a
m
b
ie
n
t 
te
m
p
e
ra
tu
re
 
~
2
5
◦ C
 
re
fr
ig
e
ra
te
d
 ~
4
◦ C
  
s
u
b
-z
e
ro
 
te
m
p
e
ra
tu
re
s
  
[107]   Ec M Pa Sa   12 B                    L  24 ?? ??  
          B     Gl               L   ?? ??  
          B      P         FD      ??  ?? ??  
          B      P           FP    ??  ?? ??  
[104]     Pa        W     T M    Le      SF  ?? NA    
             W     T M    Le     SD   ??     
[113]    M      B    Ge   A        FD      ?? 30 ??   
          B      P         FD      ??     
          B              O FD      ??     
[108]  Cu        B       A        FD      ?? 3 ??   
          B       A   S     FD      ??  ??   
[119]   Ec       B          S     FD      ?? NA    
[109]   Ec  Pa Sa  Vc 
>
4
0
0
 B                    L NA LT  ??  
         B     Gl               L     ?? 
[105]   Ec        Bu              FD      ① 4    
           Bu         S     FD      ①   ??  
[114]      Sa    B          S     FD      ① 37  ??  
          B        T       FD      ①   ??  
          B           PV          ??     
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          B       A        FD      ??     
            Sa                  L    ②  
          B                    L    ①  
          B         M      FD      ④   ⑥  
          B              O FD      ②   ⑥  
[123]      Sa     Bu   Ge     M      (FD)      ① 12  ③-④  
           Bu   Ge     M     O (FD)      ①   ③-④  
[118]   Ec        Bu       T   PV    FD      ?? 2  ⓪   
             W     T   PV    FD      ??     
           Bu          PV    FD      ??     
             W        PV    FD      ??  ⑧   
[106]   Ec        Bu              (FD)      ?? 1  ?? ?? ?? 
[120]     Pa        W     T     Le     SD    12  ①/⑦  
                   M    Le     SD       ③/⑦  
[100]     Pa Sa     Bu              (FD)      ?? 0.25 ?? ??  
[117]     Pa Sa     Bu         S     FD      ?? 1  ??  
           Bu              FD      ??   ??  
           Bu   G           FD      ??   ??  
           Bu             O FD      ??   ??  
[75]   Ec        Bu                 (SD)   ?? 12 ??   
[135]     Pa Sa     Bu           La      (SD)   ④-⑧ N/A    
           Bu       T          (SD)   ⓪-②     
           Bu             O    (SD)   ⑦-⑧     
[132]     
Pa Sa     Bu       T        
 
 SD 
  
N/A 12 ?? 
⓪-③ 
①-④ 
 
[77]       Se      W     T       (FD)      ?? 3  ??  
[131] Bc    Pa      Bu     P  T     Le O    SD   ?? 3  ??  
[116] Bc    Pa        W   P      La   FD      ② 3 ?? ??  
[157]      Sa     Bu     P        O   (AD)    - 0.5 ?? ??  
      Sa     Bu     P        O      (L)  1.5  ??  
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Table 3. Summary of bacteriophage microencapsulation literature in polymer carriers.  
R
e
f 
Host Organism Carrier system Encapsulation method Additives Target 
application 
Release 
studies 
Dimensions Structure Key Highlights 
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hydroxypropyl 
methylcellulose 
(HPMC); hyaluronic 
acid methacrylate 
(HYMA); Poly(DL-
lactide:glycolide) 
(PLGA); Polyvinyl 
alcohol (PVA); 
Polyvinyl 
pyrrolidone (PVP); 
cellulose diacetate 
(CDA); polyethylene 
oxide (PEO); whey 
protein (WP) 
water-in-oil emulsion 
(W/O); water-in-oil-in-
water double emulsion 
(W/O/W); extrusion (E); 
gelation (G); 
electrospinning (ES); wet 
spinning (WS); solvent 
evaporation (SW); 
precipitation 
polymerisation (PP); liquid 
phage filled capsules 
(LPFC) 
polysaccharides 
(PS); 
sucrose (Suc); 
other sugars (S); 
chloroform as 
solvent (Chl); 
others (O); 
aqueous 
solvent (Aq) 
food 
contamination 
(FC);  
nasal carriage 
of infectious 
organism 
(NC); 
gastrointestinal 
/ respiratory / 
wound 
infections  
(G / R / W); 
simulated 
gastric fluid 
(SGF);  
 
intestinal 
fluid (SIF);  
 
phosphate 
buffer saline 
(PBS); 
● sphere 
⌇ fibre 
◻ film 
acid exposure (AE); cascade 
impaction study (CI); storage 
studies (SS); nasal inserts (NI); 
clinical case studies (CCS); 
thermally responsive polymer 
(TR); edible coating (EC); 
exposure to degrading enzymes 
(EEnz ); exposure to bile salts 
(BS); animal studies (AS); 
exposure to bile salts (BS);  
 
+/- indicates phage protection / 
damage 
[100]     Pa    Sa  PLGA; PVA W/O/W – SE - R Buffer ~ 10 µm ● CI; SS 
[123]         Sa  HPMC Freeze drying S + O NC Sterile 
water 
 N/A  NI; SS; 
[155] Ec  L        Alginate E + G - FC N/A  N/A  SS; 
[160] Ec   P    S   Polyamide Casting Suc W PBS  N/A  SS; 
[121]    P Pa   S   Polyamide Casting Suc + O W N/A ~ 100 µm ◻ CCS 
[147]      Se     Polyamide PP - W Water ~500 nm ● TR 
[154] Ec          WP Imbibition O FC SGF/SIF ~100 µm ⌇ EC; SS; 
[156] Ec          Chitosan + alginate E + G - G SGF/SIF  N/A  AE(+); EEnz (+); BS (+) 
[149]  Ll         Skim milk + rennet W/O + G - G SGF/SIF ~ 100 µm ● AE(+); EEnz (+); 
[149]  Ll         Alginate E + G - G SGF/SIF ~ mm ● AE(-); EEnz(-); 
[149]  Ll         Alginate + WP E + G - G SGF/SIF ~ mm ● AE(+); EEnz(+); 
[144]         Sa  Alginate + WP E + G Suc; S; PS; O G - < 1 mm ● AE (+); SS; 
[145]         Sa  Alginate E + G CaCO3 G SGF/SIF < 1mm ● AE(+); EEnz(+); BS (+); 
[122] Ec          Alginate; Pectin E + G - G SGF/SIF ~ mm ● AE (+); EEnz (+) 
[143]      Se     Chitosan + alginate E + G - G SGF/SIF < 1mm ● AE(+); EEnz (+); BS (+); SS; 
[78]      Se     Alginate  E + G CaCO3 G SGF/SIF ~100 µm ● AE (+); EEnz (+); BS (+); SS; AS 
[59]      Se     Alginate  E + G Other G - -  AS; 
[75] Ec          Eudragit S100  Spray drying - G SGF -  AS; SS; 
[57] Ec          HPMC LPFC - G - -  AS 
[157]      Se     Alginate + WP E + G PS G SGF/SIF < 1 µm ● AE (+); EEnz (+); BS (+); SS; 
[101] Ec          PVP ES / WS Aq - Buffer Ø~100nm/ ~10µm  ⌇  
[152] Ec          PVA  ES Aq - Broth Ø ~500 nm ⌇ SS; 
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[151] Ec          PVA ES Aq - Broth Ø ~500 nm ⌇ SS; 
[118] Ec          PVP ES Trehalose; O - Buffer Ø ~100 nm ⌇ SS; 
[106] Ec          Alginate + PEO W/O + E + G + ES Chl FC Buffer Ø ~ µm ⌇ SS 
[106] Ec          PEO  ES (coaxial) Chl FC Buffer Ø ~ 1 µm ⌇ Core-shell; SS 
[153] Ec          PEO; CDA ES (coaxial) Chl FC Buffer Ø ~ 1 µm ⌇ Core-shell 
[148]         Sa  HYMA photo-crosslinking - - Buffer - ◻ Enzyme triggered release 
[142]         Sa  Soya bean oil O/W surfactant W - - ● Nano-emulsions 
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Table 4. Summary of bacteriophage microencapsulation literature in liposome carriers.  
Ref Host 
organism 
Carrier system Encapsulation 
method 
Additives Target 
infection 
Release 
studies 
Size Of note 
PE = Phage 
encapsulation 
outcome  
[206] S. enteritidis Softisan 100™; soybean 
PC 
Water-in-oil-in-water 
double emulsion 
Tween 80; glycerol; 
polyoxamers (Lutrol 
F68)  
Respiratory 
 
- (50-250) nm PE (modest) 
[150] E. coli; M. 
Smegmatis 
DOPC (1,2-dioleoyl-sn-
glycero-3-
phosphocholine); DOPS 
(1,2- dioleoyl-sn-glycero-
3-phospho-L-serine) 
Thin film hydration + 
PVA gel assisted 
hydration 
- Intracellular - (5–50) µm Giant unilamellar 
vesicles; 
PE (good) 
[77] S. enterica Mixture of (DLPC: Chol-
PEG600: Cholesterol: 
Cholestyrl) molar ratio 
(10:1:2:7) 
Thin film hydration + 
extrusion 
Chloroform as solvent; 
trehalose added as 
cryoprotectant 
Gastrointestinal Simulated 
gastric fluid / 
buffer 
~(200–800) 
nm 
Freeze drying; 
storage studies;  
PE (good) 
[31] K. pneumonia Phosphatidylcholine: 
Cholesterol 
Thin film hydration Tween 80; 
Stearylamine 
Respiratory - ~ 100 nm Animal studies 
[39] K. pneumonia Phosphatidylcholine: 
Cholesterol 
Thin film hydration Tween 80; 
Stearylamine; 
dicetylphosphate 
Respiratory - ~(500-1000) 
nm 
Storage studies;  
PE (good);  
[95] K. pneumonia Phosphatidylcholine: 
Cholesterol 
Thin film hydration Tween 80; 
Stearylamine 
Respiratory - ~100 nm Ex vivo biofilm 
model; Intracellular 
macrophage model; 
animal studies 
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Figure Captions 
 
Figure 1. Population dynamics of bacteria and phage. 
Blue lines – phage P1 (solid line) and P2 (dashed line). Red lines – bacteria B1 (solid line) and B2 (dashed line); B2 is resistant to P1.  
(a) – low dose of single phage (P10  10
3
 PFU/ml ) is insufficient to prevent bacteria concentration exceeding upper threshold;  
(b) - high dose of phage (P10  10
6
 PFU/ml) arrests B1 growth, but phage resistant mutant bacteria B2 grows unchecked;  
(c) and (d) - mixture of two different phage ; (c) - low dose of P2 is insufficient to prevent resistant bacteria B2 concentration exceeding upper threshold; (d) - 
high dose of both phage prevents both bacteria concentrations from reaching upper threshold. 
 
Figure 2. Population dynamics of bacteria and phage.  
Blue lines – phage concentration; red lines – bacteria concentration. 
(a), (b) – effect of phage dose (10
4
 – 10
8
 PFU/ml) and initial bacteria concentration (10
4
, 10
7
 CFU/ml);  
(c) - effect of continuous sustained delivery of phage for 1h, 4h and 10h (solid, broken and dashed lines accordingly). 
 
Figure 3. Membrane emulsification (ME) methods that can be used for phage encapsulation: (a) Cross flow ME; (b) Premix ME; (c) Shirasu Porous Glass 
(SPG) microkit; (d) Micropore Dispersion Cell; (e) Axially oscillating membrane tube. 
 
Figure 4. Morphologies of complex drops: (a) Conventional multiple emulsion drop; (b) Multiple emulsion drops generated in microfluidic channels with 
controlled number of inner drops [246] and distinct inner drops [247]; (c) Drops generated in microfluidic channels with multiple concentric shells [249]; (d) 
Janus and ternary drops generated in microfluidic channels [250,251]. 
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 (a) (b) (c) (d) 
 
Figure 1. Population dynamics of bacteria and phage. 
Blue lines – phage P1 (solid line) and P2 (dashed line). Red lines – bacteria B1 (solid line) and B2 (dashed line); B2 is resistant to P1.  
(a) – low dose of single phage (P10  10
3
 PFU/ml ) is insufficient to prevent bacteria concentration exceeding upper threshold;  
(b) - high dose of phage (P10  10
6
 PFU/ml) arrests B1 growth, but phage resistant mutant bacteria B2 grows unchecked;  
(c) and (d) - mixture of two different phage ; (c) - low dose of P2 is insufficient to prevent resistant bacteria B2 concentration exceeding upper 
threshold; (d) - high dose of both phage prevents both bacteria concentrations from reaching upper threshold. 
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 (a) (b) (c) 
 
Figure 2. Population dynamics of bacteria and phage.  
Blue lines – phage concentration; red lines – bacteria concentration. 
(a), (b) – effect of phage dose (10
4
 – 10
8
 PFU/ml) and initial bacteria concentration (10
4
, 10
7
 CFU/ml);  
(c) - effect of continuous sustained delivery of phage for 1h, 4h and 10h (solid, broken and dashed lines accordingly). 
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 (a) (b) 
 
        
 (c) (d) (e) 
 
 
Figure 3. Membrane emulsification (ME) methods that can be used for phage encapsulation: (a) Cross flow ME; (b) Premix ME; (c) Shirasu Porous Glass 
(SPG) microkit; (d) Micropore Dispersion Cell; (e) Axially oscillating membrane tube.  
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Figure 4. Morphologies of complex drops: (a) Conventional multiple emulsion drop; (b) Multiple emulsion drops generated in microfluidic channels with 
controlled number of inner drops [246] and distinct inner drops [247]; (c) Drops generated in microfluidic channels with multiple concentric shells [249]; (d) 
Janus and ternary drops generated in microfluidic channels [250,251]. 
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Graphical abstract 
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Paper Highlights: 
 Review of phage therapy studies in acute infection animal models showing the need for formulation and dosage forms 
containing stable high phage titres 
 Review of phage-bacterium pharmacodynamics literature and exploring the need for high phage titres, controlled and 
sustained release phage delivery systems capable of delivering high phage doses at the site of infection 
 Review of literature on spray drying and freeze drying of bacteriophages 
 Review of literature on phage encapsulation in microparticles, nanoparticles including liposomes and electrospun fibers 
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